Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Involving proteinase

Subclass of:

435 - Chemistry: molecular biology and microbiology

435004000 - MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF FORMING SUCH COMPOSITION OR TEST STRIP

435018000 - Involving hydrolase

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20080280316Method of Detection, Separation and Identification for Expressed Trace Protein/Peptide - A method of detection separation and identification for expressed trace protein/peptide; and a system therefor. There is provided a method of detecting, separating and identifying a minute amount of expressed protein and/or peptide, characterized in that a fluorescent derivative of protein and/or peptide contained in a test subject sample having been labeled with a fluorescence reagent is applied to HPLC; a fluorescent fraction is collected and subjected to enzymatic hydrolysis; mass-spectrometry of the resultant fluorescence-labeled fragments and non-fluorescence-labeled fragments is carried out; and the thus obtained ion molecular weight information on each of the fragments is collated with an available protein and/or peptide fragment database to thereby accomplish a structural analysis. Further, there is provided an identification system therefor.11-13-2008
20100055728ENZYME SENSORS, METHODS FOR PREPARING AND USING SUCH SENSORS, AND METHODS OF DETECTING PROTEASE ACTIVITY - Embodiments of the present disclosure provide for enzyme sensors, protease sensors, methods for producing and using the enzyme and protease sensors, methods of detecting and/or measuring protease activity, methods for characterizing protease cellular activity, fusion proteins, polynucleotides, and vectors corresponding to the enzyme and protease sensors, kits, and the like.03-04-2010
20090197290Methods and Kits for Diagnosis of Non-Septic Shock - Methods and kits for diagnosis and staging of non-septic shock are presented in which one or more protease activities are measured from a biological sample to so identify and/or stage non-septic shock. Most preferably, at least two protease activities are correlated, however, additional or alternative markers may also be measured.08-06-2009
20100184110PREDICTIVE DIAGNOSTICS FOR KIDNEY DISEASE - The present invention relates to markers for kidney disease.07-22-2010
20120183983Polymeric Reverse Micelles as Selective Extraction Agents and Related Methods of MALDI-MS Analysis - Methods for liquid-liquid extraction, as can be effected using polymeric reverse micelles, such methods as can be used in conjunction with various mass spectrometric techniques.07-19-2012
20090191581CELL-PERMEABLE FLUORESCENT PROTEINS - This invention relates to methods and compositions for designing novel fluorescent proteins, preferably to a green fluorescent proteins (GFP). The engineered GFPs are modified by substituting negatively charged amino acids with positively charged amino acids on the exterior of the protein making the protein cell permeable. The ability of the engineered fluorescent proteins to permeate cells obviates the need for transfections, allowing these novel proteins to be used in numerous biological applications.07-30-2009
20090191580METHOD OF SCREENING USING c-MET, A NOVEL SUBSTRATE FOR GAMMA-SECRETASE - The present invention relates to a method of screening for compounds which affect the processing of c-Met by γ-secretase, comprising the following steps: 07-30-2009
20100081156FLUORESCENCE POLARIZATION ASSAYS FOR DETERMINING CLOSTRIDIAL TOXIN ACTIVITY - The present invention provides a method of determining the presence or activity of a clostridial toxin by (a) treating with a sample, under conditions suitable for clostridial toxin protease activity, a clostridial toxin substrate which includes a fluorophore; a bulking group; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the fluorophore and the bulking group; (b) exciting the fluorophore with plane polarized light; and (c) determining fluorescence polarization of the treated substrate relative to a control substrate, where a change in fluorescence polarization of the treated substrate as compared to fluorescence polarization of the control substrate is indicative of the presence or activity of the clostridial toxin.04-01-2010
20100081155FLUORESCENCE POLARIZATION ASSAYS FOR DETERMINING CLOSTRIDIAL TOXIN ACTIVITY - The present invention provides a method of determining the presence or activity of a clostridial toxin by (a) treating with a sample, under conditions suitable for clostridial toxin protease activity, a clostridial toxin substrate which includes a fluorophore; a bulking group; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the fluorophore and the bulking group; (b) exciting the fluorophore with plane polarized light; and (c) determining fluorescence polarization of the treated substrate relative to a control substrate, where a change in fluorescence polarization of the treated substrate as compared to fluorescence polarization of the control substrate is indicative of the presence or activity of the clostridial toxin.04-01-2010
20100075358FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS - The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.03-25-2010
20080305508Methods of screening for compounds that modulate TAFIa activity, compounds, and methods of using the compounds - Provided are methods of screening compounds for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compounds identified by the screening methods can be used to treat, prevent or manage in a patient pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder. Also provided is a method of evaluating test compounds for TAFI inhibitory activity wherein the TAFI inhibitory activity of these test compounds is compared to the TAFI inhibitory activity of aspirin or its derivatives or metabolites. Further provided is a method of treating, preventing or managing in a patient, a hemorrhagic or thrombotic disease or disorder with high dose aspirin or aspirin derivatives or metabolites. Also contemplated is a method of treating, preventing or managing in a patient, pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder comprising administering aspirin or a derivative thereof or any other therapeutic having at least one desired therapeutic or prophylactic activity of aspirin to a patient in need thereof and administering to the patient a factor that promotes TAFIa activity, e.g. stabilized TAFIa, to ameliorate one or more adverse side effects of the therapeutic. Compounds identified by the methods of the invention are also provided.12-11-2008
20110195442STERILITY INDICATING BIOLOGICAL COMPOSITIONS, ARTICLES AND METHODS - A sterility indicating composition comprising a plurality of sterilization process resistant spores which contain an active protease during germination and initial outgrowth of the spores; and a germination medium comprising at least one labeled protease substrate and at least one nutrient for germination of the spores; wherein the medium is essentially free of a) any active protease other than the active protease contained by the plurality of spores and b) any protease substrate other than the at least one labeled protease substrate, other than any protease substrate originating from the plurality of spores, and other than any protease substrate which does not compete with the labeled protease substrate for the active protease; and wherein the at least one labeled protease substrate comprises a peptide which can be cleaved by the active protease and which is labeled with one or more dye groups, at least one of which undergoes a detectable change when the peptide is cleaved by the active protease, and wherein the labeled protease substrate is stable at least at a temperature for incubating the spores, a sterilization process indicator comprising the composition, and a method of determining the effectiveness of a sterilization process using the composition and indicator are disclosed.08-11-2011
20130115646METHOD FOR MEASURING GLYCATED HEMOGLOBIN - It is to provide a method for measuring glycated hemoglobin in a hemoglobin-containing sample, comprising: reacting glycated hemoglobin in the hemoglobin-containing sample with a proteolytic enzyme in the presence of at least one salt selected from the group consisting of a pyridinium salt, a phosphonium salt, an imidazolium salt, and an isoquinolinium salt; reacting the obtained reaction product with fructosyl peptide oxidase; and measuring the generated hydrogen peroxide. The present invention provides a method for accurately measuring glycated hemoglobin in a hemoglobin-containing sample.05-09-2013
20100041087Detection of Specific Binding Reactions Using Magnetic Labels - The present invention is a novel biosensor composed of mOrange2 and mCherry fluorescent proteins operably linked via a linker, which provides a distinct color change upon separation of the fluorescent proteins.02-18-2010
20090221015Detecting Diastolic Heart Failure by Protease and Protease Inhibitor Plasma Profiling - Disclosed herein are methods of detecting and predicting diastolic heart failure and predicting congestive heart failure comprise protease and protease inhibitor profiling.09-03-2009
20130029367COMPOSITIONS AND METHODS FOR MONITORING BREAST CANCER TREATMENT - The present invention provides compositions and processes for preparing the same wherein the compositions are useful for monitoring breast cancer treatment.01-31-2013
20130071867Method And Apparatus For Performing Mass Spectrometry - The invention feature devices and methods for preserving and processing samples comprising a fluid having deuterated compounds. The device of the present invention comprises a housing defining a first chamber and a second chamber. The first chamber is heated to an elevated temperature and receives the sample and performs a digestion process on the sample at the elevated temperature. The second chamber is cooled to a low temperature and receives the deuterated digested sample from the first chamber and performs one or more separation steps to isolate an analyte. The device of further comprises conduit means for containing and moving the sample into the first chamber to form a digested sample. The conduit means moves the digested sample from the first chamber to the second chamber to separate the sample to form at least one analyte. The analyte is maintained at the low temperature to preserve its deuterated form.03-21-2013
20090093010Method of Detecting Kidney Dysfunction - Methods and kits for monitoring kidney function, and detecting kidney dysfunction and transplant related disease and rejection are disclosed. The method involves analyzing a sample, such as a urine sample, containing protein from an animal for fragments of β2-microglobulin, wherein the presence of specific β2-microglobulin fragments is indicative of kidney dysfunction and transplant rejection. In another embodiement, urine samples from an animal are tested for protease activity, such as cathepsin D or napsin A, wherein increased protease activity compared to a control sample is indicative of kidney dysfunction.04-09-2009
20130059321Labeling of Proteins with the Fluorophore 7-amino-4-methylcoumarin (AMC) Generated Novel Proteolytic Substrates - A method of measuring the degradation of intact proteins includes a step of providing a protein substrate having one or more free or exposed carboxyl groups and then reductively attaching 7-amino-4-methylcoumarin (AMC) to the protein substrate with a reducing agent. The protein substrate is contacted in a test solution with one or more proteolytic enzymes that degrade the protein substrate. The amount of AMC attached to the protein substrate is then determined by monitoring the fluorescence of free 7-amino-4-methylcoumarin that is formed during degradation of the protein substrate to protein fragments.03-07-2013
20090233321Reducing/Oxidizing Activity of Maternal Urine As Indicator of Fetal Gender Related Characteristics - The present invention provides a method for determining the gender of an unborn child by assaying the overall reducing/oxidizing or redox activity of the maternal urine or other body fluid. The method can be used to determine fetal gender at any time point during the entire pregnancy, the earliest being the first day of a missed menstruation. The body fluid may be processed before assaying. Processing may involve aging the body fluid, or purification of various fractions. The methods of the present invention also provide for a means for pre-conception baby gender planning by assaying the overall redox activity of a non-pregnant female's urine or other body fluid. The overall redox activity of a urine sample correlates with the gender specific compatibility of the ovum being released during a particular menstrual cycle. Therefore, assaying the overall redox activity of a non-pregnant female's urine will help a couple conceive a baby having a desired gender.09-17-2009
20120115177Compositions and Methods for Diagnosis of Shock - Methods and kits for diagnosis and staging of shock, and especially non-septic shock are presented in which protease activities and/or volatile compounds are measured from a biological sample to so identify and/or stage shock.05-10-2012
20080311606Platelet Activation Markers and Predictors of Desease and of Response to Therapy and for Monitoring Therapeutic Progress - Methods for assessing patient risk for platelet-affected disease states are disclosed. Also disclosed are methods for predicting the appropriateness of platelet antagonist therapy, and for monitoring patients during therapeutic intervention or during a combined regimen of therapy and angioplasty.12-18-2008
20100003709Crystal Structure of Enzyme and Uses Thereof - This invention relates to crystallised human neutrophil elastase and the use of its three-dimensional structure to design modulators for human neutrophil elastase.01-07-2010
20120237962MCAM AS A BIOMARKER FOR FLUID HOMEOSTASIS - The application discloses MCAM as a new biomarker for fluid homeostatic imbalance; methods for predicting, diagnosing, prognosticating and/or monitoring fluid homeostatic imbalance based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.09-20-2012
20130164770SYSTEM AND METHODS OF LOG-SCALE CONCENTRATION GRADIENTS - Devices and methods use an integrated microfluidic system that has the capability of realizing a wide range of accurate dilutions in a logarithmic way through semi-direct dilution of samples inside a chip. The device for dose response analysis is able to contain a first fluid source on a microfluidic chip, wherein the first fluid source comprises a drug, a second fluid source on the microfluidic chip, a mixing area on the microfluidic chip fluidically coupling with the first and the second fluidic source, and a detection area coupling with the mixing area for drug information detection using a detection system.06-27-2013
20130023005Coupling of Liquid Chromatography with Mass Spectrometry by Liquid Sample Desorption Electrospray Ionization (DESI) - An apparatus to separate and analyze components of a liquid sample include a high performance liquid chromatograph with a mass spectrometer utilizing desorption electrospray ionization. This permits separation and evaluation of different components in a liquid sample. Further, this can be combined with online derivation via reactive DESI and, further, can be used with further electrochemistry.01-24-2013
20130023004FLUOROGENIC SUBSTRATE FOR ADAMTS13 - Disclosed are fluorogenic substrates for measuring ADAMTS13 activity or ADAMTS13 inhibitor activity. Substrates can comprise an oligopeptide which can consist of up to 80 amino acids of sequence of von Willebrand Factor (VWF). The oligopeptide can include modifications of sequence of VWF, including an amino-terminal glycine, a scissile Y-M peptide, and a cysteine substitution located from 1 to 12 amino acids from the scissile Y-M in the carboxy terminal direction. A substrate can further comprise a fluorophore and a fluorescence quencher bound to the oligopeptide on opposite sides of the scissile Y-M peptide, wherein the fluorescence quencher is not identical to the fluorophore. An oligopeptide can be encoded by a nucleic acid sequence which can also encode a His tag. An oligopeptide can be expressed in a cell or microorganism. Also disclosed are methods of using a fluorogenic substrate to measure ADAMTS13 activity or ADAMTS13 inhibitor activity.01-24-2013
20110117588METHOD OF PREDICTING DRUG-INDUCED PHOSPHOLIPIDOSIS - The present invention provides a method of predicting drug-induced phospholipidosis, comprising a step of contacting a mammalian cell with a test compound, a step of measuring extracellular and/or intracellular lysosomal enzyme level or activity, or measuring intracellular LC3 level, and a step of selecting a test compound that has enhanced extracellular secretion of the enzyme or increased the protein level as a compound capable of inducing drug-induced phospholipidosis.05-19-2011
20100178659METHOD OF MEASURING HbA1c - A method of measuring HbA1c is provided that, even with a whole blood sample after storage, measurement accuracy substantially equal to a whole blood sample right after collection can be maintained. Whole blood is stored in a presence of a glycolytic inhibitor and protease is added to the stored whole blood sample to cleave hemoglobin in the whole blood sample. Then a glycated part of a hemoglobin fragment thereby obtained is treated with fructosyl amine oxidase. Thereafter, a glycation degree of HbA1c is determined by measuring a redox reaction between the glycated part and the fructosyl amine oxidase. Further, instead of storage of the whole blood in a presence of the glycolytic inhibitor, a strong electrolyte substance such as KCl, K07-15-2010
20100311096IDENTIFYING MOLECULES MODULATING PROTEIN-PROTEIN INTERACTIONS USING PROTEASE ACTIVATED REPORTERS - Assay methods and systems use enzymatic cleavage resulting from protein-protein interaction to modulate (activate or inactivate) a reporter.12-09-2010
20110143385PLASMA MEMBRANE VESICLES AND METHODS OF MAKING AND USING SAME - The instant invention provides plasma membrane vesicles, methods of making the same, and method of using the plasma membrane vesicles.06-16-2011
20110294150IMMUNOGLOBULIN GLYCOSYLATION PATTERN ANALYSIS - The current invention is directed to a method for the determination of the glycosylation pattern of a human immunoglobulin of the subclass IgG1 or IgG4 or of a murine immunoglobulin of the subclass Ig-G2a or IgG3 comprising the following steps: a) cleaving said immunoglobulin into fragments by enzymatic digestion with the enzyme IdeS, b) separating the fragments of said immunoglobulin obtained by the enzymatic digestion by reversed phase high performance liquid chromatography, c) subjecting the separated fragments of said immunoglobulin obtained in step b) to a mass spectrometric analysis, and d) determining the glycosylation pattern of said immunoglobulin from the mass spectrometric data obtained in step c).12-01-2011
20110294149Alzheimer's Disease Secretase, APP Substrates Therefor, and Uses Therefor - The present invention provides the enzyme and enzymatic procedures for cleaving the β secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.12-01-2011
20090035797Detection of Disease Associated Proteolysis - Described herein are methods and techniques to study the “degradome”. The degradome of a specific protease is the complete product of the natural substrate repertoire of that enzyme in a cell, tissue or organism. The complete set of proteases that are expressed at a particular moment or circumstance by a cell, tissue or organism produces the collective degradome. Included in the methods described herein are approaches that allow the direct identification and characterization of degradome peptides from approx. 400 to approx. 12,000 Da. The methods of the invention avoid the inherent problems of studying the peptidome by focusing on specific or unique proteolytic cleavages that occur as a result of endogenous protease activity induced by specific diseases. Once characterized, the presence of, or change in level of, specific peptides of the degradome can be used, e.g., to identify specific peptides having elevated levels compared to a reference normal/or to correlate identified peptides with specific proteins and/or to identify protein fragmentation patterns (e.g., peptide ladders) and the specific protease(s) that brought them about and then correlate this information with the presence or absense of a specific disease or condition. Thus, the methods of the invention can be used, for example, to identify new diagnostic markers and/or therapeutic targets, as specific clinical diagnostic methods for individual patients and as methods of monitoring the progress of a therapeutic regimen for the treatment of a patient.02-05-2009
20080293084FLUORESCENCE POLARIZATION ASSAYS FOR DETERMINING CLOSTRIDIAL TOXIN ACTIVITY - The present invention provides a method of determining the presence or activity of a clostridial toxin by (a) treating with a sample, under conditions suitable for clostridial toxin protease activity, a clostridial toxin substrate which includes a fluorophore; a bulking group; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the fluorophore and the bulking group; (b) exciting the fluorophore with plane polarized light; and (c) determining fluorescence polarization of the treated substrate relative to a control substrate, where a change in fluorescence polarization of the treated substrate as compared to fluorescence polarization of the control substrate is indicative of the presence or activity of the clostridial toxin.11-27-2008
20100297683METHOD - The present invention provides a method for the detection of a protease comprising the use of a substrate partially coated with a film of a synthetic polymeric matrix comprising a peptide of up to 20 amino acids. Apparatus for performing such methods is also disclosed.11-25-2010
20110217720Compositions and Kits Pertaining to Analyte Determination - This invention pertains to methods, kits and/or compositions for the determination of analytes by mass analysis using unique labeling reagents or sets of unique labeling reagents. The labeling reagents can be isomeric or isobaric and can be used to produce mixtures suitable for multiplex analysis of the labeled analytes.09-08-2011
20090098590ENDOTOXIN ANALYSIS - The present invention relates to a method for detecting the presence or non-presence of an endotoxin, characterized in that an OmpT protein is brought into contact with a sample suspected of containing an endotoxin and the protease activity of the OmpT protein is assayed. It also relates to a method for detecting early onset of septicaemia using the inventive method and a kit for performing the method.04-16-2009
20090191582ENZYME DETECTION - An enzyme detection product (07-30-2009
20100035291METHOD FOR DEGRADING PEPTIDES, METHOD FOR ANALYZING PEPTIDES, DEVICE FOR DEGRADING PEPTIDES AND DEVICE FOR ANALYZING PEPTIDES - A fragmenting reaction of peptide is achieved while maintaining the isolated state of peptide. Isolated peptide fractions isolated by electrophoresis are prepared in flow paths. Subsequently, prepared peptide fractions are dried by each of the flow paths. Then, dried peptide fractions are in contact with protease. Then, independent liquid membranes of a solvent are formed over the surfaces of peptide fractions, which have been in contact with protease, disposed on the flow paths, respectively.02-11-2010
20100112621Analytical Method for Protein Mapping Using Hydrogen/Deuterium Exchange - Analytical methods using hydrogen/deuterium exchange are provided which reduce or eliminate the back-exchange of deuterium for hydrogen. The methods, which are useful in protein and peptide mapping, include the steps of (a) providing a peptide or protein comprising a solvent accessible hydrogen; (b) exchanging the solvent accessible hydrogen for a deuterium; (c) separating the peptide or protein with supercritical fluid chromatography; and (d) analyzing by mass spectrometry the mass of the separated peptide or protein. Supercritical fluid chromatography enables the observation of fast exchanging hydrogen atoms missed using conventional liquid chromatography methods.05-06-2010
20110195441 METHOD AND ASSEMBLY FOR MEASURING THROMBIN GENERATION IN PLASMA - Disclosed is a method for measuring thrombin generation in a whole blood sample. The whole blood sample may be applied forthwith, without prior processing. The blood cells and blood plasma in the whole blood sample are separated by (lateral) flow migration. Also disclosed is an assembly of a sample support and a device dedicated to measure thrombin generation in a whole blood sample. Advantageously, the sample support comprises a separator medium allowing separation of whole blood into blood cells and blood plasma by means of (lateral) flow migration.08-11-2011
20100267070PHARMACEUTICAL COMPOSITIONS FOR THE TREAMENT OF CONDITIONS RESPONSIVE TO PROTEASOME INHIBITION - The invention disclosed herein generally relates to methods and compositions for inhibiting proteasome activity comprising a syrbactin compound have the structure of Formula (I) or (II).10-21-2010
20090004684Compositions and Methods for Detection and Quantification of Protein Oxidation - Compositions and methods for detecting carbonyl functional groups on polypeptides are disclosed.01-01-2009
20100081158FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS - The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.04-01-2010
20120107859METHODS FOR EARLY DETECTION OF BLOOD DISORDERS - Disclosed herein are methods of detecting blood disorders, such as diabetes. In particular examples the method includes contacting a blood sample with an amine reagent, blocking an excess of the amine reagent with a blocking reagent, digesting the modified blood sample with trypsin to produce a digested blood sample containing a plurality of glycated N-terminal peptides and non-glycated N-terminal peptides, then analyzing the digested blood sample with MALDI MS. Also provided are reagents for use in such methods.05-03-2012
20120107858CANCER DIAGNOSIS METHOD USING THE GLYCOSYLATION OF A GLYCOPROTEIN - The present invention relates to a cancer diagnosis method using peptides containing information on the glycosylation of a glycoprotein involving cancer development. More particularly, the present invention relates to a cancer diagnosis method which obtains peptides from the glycoprotein involving cancer development through a hydrolysis process using an enzyme, and quantitatively detects, from among the thus-obtained peptides, glycosylation-related specific peptides which are influenced by the glycosylation of proteins and show specific quantitative changes in the hydrolysis process, to thereby select glycosylation-related specific peptides which show specific quantitative changes in accordance with cancer development. The cancer diagnosis method of the present invention uses the thus-selected glycosylation-related specific peptides as a marker.05-03-2012
20120107857Di- and Poly-Ubiquitin Deubiquitinase Substrates and Uses Thereof - Methods for detection of the activity of proteolytic enzymes, particularly isopeptidases, are disclosed.05-03-2012
20120107856New Fungal Production System - The present invention provides a new fungal production system comprising a fungal host strain of 05-03-2012
20090203059PROTEASE DETECTION PRODUCT - A protease detection product (08-13-2009
20110171675FRET-BASED MEMBRANE-TYPE 1 MATRIX METALLOPROTEINASE BIOSENSOR AND METHODS FOR USING THE SAME - The present invention is a novel FRET-based biosensor composed of ECFP and YPet fluorescent proteins operably linked via a MT1-MMP recognition sequence for use in the detection of cancer cells in a biological sample.07-14-2011
20090286270METHOD FOR TREATING PERVASIVE DEVELOPMENT DISORDERS - A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with a PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level.11-19-2009
20090017482Luminogenic and nonluminogenic multiplex assay - A method to detect the presence or amount of at least one molecule for an enzyme-mediated reaction in a multiplex luminogenic/nonluminogenic assay is provided.01-15-2009
20120295294ENZYMATIC METHOD FOR PREPARING ASPARTAM - An improved method is described for the synthesis of aspartame using a condensation reaction between the alpha-carboxyl group of the L-aspartic acid and the amino group of the methyl L-phenylalaninate catalyzed by an enzyme. The method allowed efficient and cost effective production of aspartame. A method of identifying an enzyme useful for preparing aspartame is also described.11-22-2012
20120295293NOVEL ENHANCED SURFACE AREA CONICO-CYLINDRICAL FLASK (ES-CCF) FOR BIOFILM CULTIVATION - A novel enhanced surface area conico-cylindrical flask (ES-CCF) providing increased surface area by virtue of its' inner arrangement and useful in routine small-scale studies of bioactives production by any biofilm-forming marine as well as terrestrial microorganisms. Compared to corresponding Erlenmeyer flask of similar volume the ES-CCF provides more than 80% additional surface for biofilm attachment and growth. The ES-CCF does not require steam sterilization and is durable as the device is constructed of polymethyl methacrylate or any other such hydrophobic material and offers possibility of altering the nature of the growth surface (hydrophilic and hydrophobic). The ES-CCF also provides external aeration like a bioreactor, thus increasing the versatility of applications. Further, the device can be operated as a cylindrical flask, that is without the inner arrangement.11-22-2012
20090035799NOVEL TRYPSIN FAMILY SERINE PROTEASES - Two novel trypsin-family serine proteases specifically expressed in adult mouse testis (“Tespec PRO-1” and “Tespec PRO-2”), and a novel trypsin-family serine protease derived from mouse (“Tespec PRO-3”) have been isolated. Also, two novel trypsin-family serine proteases derived from human (“Tespec PRO-2” and “Tespec PRO-3”) have been isolated. It has been suggested that these proteins are involved in sperm differentiation and maturation, and sperm functions (e.g., fertilization). Therefore, these proteins are useful for development of novel therapeutics and diagnostics for infertility, as well as for development of novel contraceptives.02-05-2009
20090035798Methods for Reducing the Immunogenicity of Cytokines and Removal of Cell Surface Markers - The present invention provides means to assess the comparative allergenicity of proteases. In particular, the present invention provides means to qualitatively assess the potential for any protease to induce an allergic response in humans. In addition, the present invention provides means to select proteases with reduced allergenicity for use in various applications.02-05-2009
20110201039IMPROVED VIRAL PROTEIN QUANTIFICATION PROCESS AND VACCINE QUALITY CONTROL THEREWITH - A process of quantifying proteins in a complex mixture is provided. The invention has utility in quantifying proteins in a complex preparation of uni- or multivalent commercial or research vaccine preparations.08-18-2011
20080293083Method and Kit for Peptide Analysis - The present invention relates to a method for peptide analysis, comprising the following steps: a) tagging N-terminals of peptides in sample(s) with mass tagging reagent(s) and mass balancing C-terminals of said peptides with mass balancing reagent(s), or vice versa; and b) mass spectrometry analysis of said peptides. The present invention also relates to a kit with global mass tagging reagents and mass balancing reagents for use in said method and a database with specific peptide information.11-27-2008
20080280317Comprehensive Characterization Of Complex Proteins At Trace Levels - A combination of “bottom up” and “top down” MS analysis of posttranslational modifications in complex proteins is described. The method comprises digestion of the protein with an enzyme that forms larger peptide fragments than trypsin (>3000 D), performing HPLC with the fragments and applying a new data acquisition strategy using on-line coupling with e.g. LTQ-FTMS, a hybrid mass spectrometer that couples a linear ion trap with a Fourier transform ion cyclotron resonance (FTICR) cell. The method is applied to analysis of posttranslational modifications of protein isoforms.11-13-2008
20080293085FLUORESCENCE POLARIZATION ASSAYS FOR DETERMINING CLOSTRIDIAL TOXIN ACTIVITY - The present invention provides a method of determining the presence or activity of a clostridial toxin by (a) treating with a sample, under conditions suitable for clostridial toxin protease activity, a clostridial toxin substrate which includes a fluorophore; a bulking group; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the fluorophore and the bulking group; (b) exciting the fluorophore with plane polarized light; and (c) determining fluorescence polarization of the treated substrate relative to a control substrate, where a change in fluorescence polarization of the treated substrate as compared to fluorescence polarization of the control substrate is indicative of the presence or activity of the clostridial toxin.11-27-2008
20080305510FLUORESCENCE POLARIZATION ASSAYS FOR DETERMINING CLOSTRIDIAL TOXIN ACTIVITY - The present invention provides a method of determining the presence or activity of a clostridial toxin by (a) treating with a sample, under conditions suitable for clostridial toxin protease activity, a clostridial toxin substrate which includes a fluorophore; a bulking group; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the fluorophore and the bulking group; (b) exciting the fluorophore with plane polarized light; and (c) determining fluorescence polarization of the treated substrate relative to a control substrate, where a change in fluorescence polarization of the treated substrate as compared to fluorescence polarization of the control substrate is indicative of the presence or activity of the clostridial toxin.12-11-2008
20080305509FLUORESCENCE POLARIZATION ASSAYS FOR DETERMINING CLOSTRIDIAL TOXIN ACTIVITY - The present invention provides a method of determining the presence or activity of a clostridial toxin by (a) treating with a sample, under conditions suitable for clostridial toxin protease activity, a clostridial toxin substrate which includes a fluorophore; a bulking group; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the fluorophore and the bulking group; (b) exciting the fluorophore with plane polarized light; and (c) determining fluorescence polarization of the treated substrate relative to a control substrate, where a change in fluorescence polarization of the treated substrate as compared to fluorescence polarization of the control substrate is indicative of the presence or activity of the clostridial toxin.12-11-2008
20080233605Method of Assaying Glycated Protein - The present invention provides a convenient, efficient method for assaying glycated protein, fructosyl peptide, or fructosyl amino acid which can be performed with reduced effect of fructosyl lysine compounds. The invention also provides a reagent for the assay.09-25-2008
20110207161METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble CD44 antigen, Angiopoietin-1, soluble Angiopoietin-1 receptor, C—X—C chemokine motif 5, soluble Endoglin, soluble Tumor-associated calcium signal transducer 1, Erythropoietin, soluble Fractalkine, Heme oxygenase 1, soluble Interleukin-1 receptor type II, soluble Interleukin-6 receptor subunit-alpha, Lymphotactin, Lymphotoxin-alpha, Stromelysin-1, C—C motif chemokine 22, C—C motif chemokine 5, and Thrombospondin-1 as diagnostic and prognostic biomarkers in renal injuries.08-25-2011
20080241867Apparatuses and methods for determining protease activity - The present invention relates to compositions and an apparatuses for determining protease activity. The compositions of the invention contain a reporter protein fused to at least one protease cleavage sequence, and a linker for attaching the protease cleavage sequence to a solid support. Methods for determining protease activity and characterizing proteases are also provided.10-02-2008
20120070856CROSS-LINKING AGENTS - The invention relates to a protein cross-linking agent of the formula, where R03-22-2012
20090136981METHODS OF MEASURING CELL VIABILITY IN TISSUE ENGINEERED PRODUCTS - This invention provides methods of measuring the viability of cultured cells by detecting one or more cell death-stable proteins or enzyme activities. Methods provided by the invention correlate viability to relative levels of enzyme activity in cell-containing and non-cell-containing fractions of a cell culture.05-28-2009
20090186370DIAGNOSTIC BIOMARKERS FOR VASCULAR ANEURYSM - Biomarkers for diagnosis and monitoring of vascular aneurysms are described in the context of the use of assays to measure a plurality of these biomarkers. Tissue degeneration, particularly elastin and/or collagen degradation, can be monitored within patient blood (serum) and/or urine to diagnose the presence, the progression, or the likelihood of rupture of aneurismal disease. Additionally, enzymes responsible for this degradation and other biomarkers responsible for the activation or inhibition of these enzymes can be monitored additionally or alternatively. Prompt diagnosis can provide the opportunity for intervention and potentially increase the health of patients by tempering the development of debilitating and life-threatening vascular aneurysms.07-23-2009
20090325208Biosynthesis of Salinosporamide A and Analogs and Methods Thereof - The present invention relates to a sahnosporamide A composition and methods of making salinosporamide A and analogs thereof. The present invention also relates to methods of identifying 2OS proteasome inhibiting agents.12-31-2009
20090023174METHODS AND COMPOSITIONS FOR DETECTING IMMUNE RESPONSES - Methods and compositions for detecting immune responses and antigen-specific cells are described herein.01-22-2009
20130217057Compositions, Methods and Kits for Diagnosis of Lung Cancer - Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC)08-22-2013
20130217058Assay for Monitoring Parathyroid Hormone (PTH) Variants by Tandem Mass Spectrometry - Methods are described for monitoring the amounts of PTH variants in a biological sample by digesting the sample to produce surrogate peptides specific to the targeted PTH variants, and detecting and quantifying the surrogate peptides by selective reaction monitoring (SRM) mass spectrometry, using a set of precursor-to-product ion transitions optimized for sensitivity and selectivity. The PTH variants, or a portion thereof, may be concentrated in the sample by means of immunoaffinity capture or other suitable technique. The mass spectrometric method described herein enables the concurrent measurement of peptides representative of a plurality of targeted PTH variants in a single assay.08-22-2013
20110143384METHODS OF PEPTIDE MODIFICATION - The present invention relates to a method of improving the resistance of a peptide or peptidomimetic to degradation by trypsin which comprises incorporating into said peptide or peptidomimetic a C-terminal capping group of formula (I): X—Y—Z (I) wherein X is a N atom, which may be substituted by a branched or unbranched C06-16-2011
20110143386METHOD FOR THE ANALYSIS OF O-LINKED OLIOSACHARIDES - A method of analyzing O-linked oligosaccharides in a sample is disclosed. The method comprises the steps of digesting a glycoprotein with a proteolytic enzyme, performing solid-phase permethylation of the oligosaccharide, then analyzing the permethylated and non-reduced O-linked oligosaccharides using MALDI-TOF mass spectrometry.06-16-2011
20090104639BIOMARKERS FOR MOTOR NEURON DISEASE - The invention provides methods of determining a diagnosis or prognosis of motor neuron disease in a mammal comprising determining the expression level of one or more proteins or polypeptides of the renin-angiotensin system in a sample taken from a subject. Similarly, aberrant post-translational modification of the proteins or polypeptides as compared to a negative control indicates a diagnosis of disease.04-23-2009
20090053746FRET PROTEASE ASSAYS FOR BOTULINUM SEROTYPE A/E TOXINS - The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.02-26-2009
20090117604PROTEOLYTIC ENZYMES IN URINE AS DIAGNOSTIC PARAMETERS IN DISEASES INVOLVING MATRIX REMODELLING - The present invention relates to a method for determining whether a urine sample has been obtained from a subject suffering from a kidney disorder involving kidney damage. The method is based on determining the level of a proteolytic enzyme in urine from the subject sample and optionally comparing this level with a reference value. The proteolytic enzyme preferably is a matrix metalloproteases, in particular MMP-2 or MMP-9. The method is particularly suitable for subjects with a condition or disorder that is associated with an increased risk of kidney disorders, such as diabetes. The method may advantageously be applied for early detection of kidney damage, in particular when the subject does not yet show any sign of microalbuminuria. The method may also be applied to a subject undergoing dialysis for determining whether the subject is suffering from remodelling of the peritoneal membrane. Thus, the method is particularly suited for patients undergoing continuous ambulatory peritoneal dialysis.05-07-2009
20110229922SCREENING ASSAYS FOR THE IDENTIFICATION OF BACE2 INHIBITORS - The present invention relates to screening assays for the identification of BACE2 inhibitors.09-22-2011
20090221016MODIFIED TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME AND METHODS OF USE THEREOF - The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.09-03-2009
20090197289METHOD FOR CONFIRMING A DIAGNOSIS OF AUTISM - A method for confirming a diagnosis of autism in of an individual comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and comparing the quantitative level of fecal chymotrypsin in the stool sample of the person having autism to a stool sample from an individual that has a normal fecal chymotrypsin level and does not have autism and confirming a diagnosis of autism based on the measurement of the quantitative level of fecal chymoptrypsin.08-06-2009
20090258381Methods for Determining the Cleavability of Substrates - The invention relates to methods for examining the enzymatic cleavability of substrates. In the methods, compounds, which have a cleavability of the section to be examined, are firstly synthesized on a first solid phase, separated therefrom, the cleavage reaction is carried out in solution and the cleaved and uncleaved compounds are immobilized on a second solid phase and the cleavability is determined.10-15-2009
20090246814REAGENT FOR DIGESTION OF HEMOGLOBIN - The present invention relates to a reagent for digestion of hemoglobin comprising a buffer, pepsin and a 10-01-2009
20090275068Method of determining chymase activity with secretory leukocyte protease inhibitor - It is now discovered that human chymase cleaves human SLPI at a specific site and that this cleavage can be used as an indicator of chymase activity. The present invention provides methods of diagnosing a chymase-associated disease or evaluating the efficiency of a treatment of a chymase-associated disease in a human subject by measuring SLPI processing, as well as other related methods and compositions.11-05-2009
20120196310A-FUCOSYLATION DETECTION IN ANTIBODIES - This invention describes a new analytical method to determine the quantity and distribution of fucose per Fc within an antibody preparation.08-02-2012
20100261215NON-INVASIVE METHOD FOR COLLECTING BIOLOGICAL DATA FOR ESTABLISHING A DIAGNOSIS OF A CUTANEOUS PATHOLOGY - A non-invasive method for collecting biological data useful for establishing a diagnosis or a prognosis of a particular cutaneous pathology in a patient, includes: 10-14-2010
20100227352Expression Quantification Using Mass Spectrometry - In various aspects, the present teachings provide systems, methods, assays and kits for the absolute quantitation of protein expression. In various aspects, the present teachings provide methods of determining the concentration of one or more proteins of interest in one or more samples of interest. In various aspects, the present teachings provide methods of determining the absolute concentration of one or more isoforms of a to protein using standard samples of signature protein fragments and parent-daughter ion transition monitoring (PDITM). In various embodiments, the absolute concentration of multiple isoforms of a biomolecule in a sample, multiple proteins in a biological process, a combination of multiple samples, or combinations thereof, can be determined in a multiplex fashion using the present teachings. In various aspects, provided are methods of assessing the response of a biological system to a chemical agent.09-09-2010
20100227353Rapid Peptidoglycan-Based Assay for Detection of Bacterial Contamination - The invention relates to a colorimetric method for detecting bacterial or fungal pathogens by detecting peptidoglycan or (1-3)-β-D-glucan in a sample.09-09-2010
20100255522Screening Method Utilizing Novel Substrate EphA7 for Gamma-Secretase - The present invention provides a method of screening for compounds which affect the processing of EphA7 by γ-secretase, comprising the following steps: 10-07-2010
20090042231FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS - The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.02-12-2009
20090042230FLEA ALLANTOINASE PROTEINS AND USES THEREOF - The present invention relates to flea allantoinase proteins; to flea allantoinase nucleic acid molecules, including those that encode such flea allantoinase proteins; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such inhibitory compounds, particularly those that specifically inhibit flea allantoinase activity, as well as the use of such therapeutic compositions to treat animals.02-12-2009
20090075315NOVEL HUMAN LYSOSOMAL PROTEIN AND METHODS OF ITS USE - The gene associated and causative of classical late infantile neuronal ceroid lipofuscinosis (LINCL), CLN2, has been identified and characterized. The translation product of this gene is a novel protease and a deficiency in this activity results in LINCL. Identification of CLN2 will not only aid in the prevention of LINCL through genetic counseling but provides strategies and test systems for therapeutic intervention. In addition, further characterization of this previously unknown lysosomal enzyme may provide useful insights into other more common human neurodegenerative disorders. Finally, the utility of a general approach for determining the molecular bases for lysosomal disorders of unknown etiology has been demonstrated.03-19-2009
20090075316Alzheimer's Disease Secretase, APP Substrates Therefor and Uses Therefor - The present invention provides the enzyme and enzymatic procedures for cleaving the β secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.03-19-2009
20100196941Multi-Analyte Analysis of Saliva Biomarkers as Predictors of Periodontal and Pre-Implant Disease - The present invention relates to methods of measuring biomarkers to determine the probability of a periodontal and/or peri-implant disease. More specifically, the invention provides a panel of biomarkers that, when used in combination, can allow determinniation of the probability of a periodontal and/or peri-implant disease state with extremely high accuracy.08-05-2010
20100196940METHODS RELATED TO CELL SURFACE GLYCOSYLATION - The present disclosure provides methods for assessing the glycosylation of a target glycoprotein produced by a cell through analysis of cell-surface glycans on the cell. The present disclosure therefore teaches that glycosylation of cell surface proteins can serve as a proxy for glycosylation of other proteins.08-05-2010
20090246815PROTEASE DETECTION MATERIAL, SET OF PROTEASE DETECTION MATERIALS, AND METHOD FOR MEASURING PROTEASE - The present invention provides a protease detection material having, on a support, at least a layer containing a dye precursor and a layer which contains a protease substrate and is disposed on the same side of the support as the layer containing the dye precursor and farther from the support than the layer containing the dye precursor, wherein the layer containing the protease substrate further contains a development center-forming substance. Further, a set of protease detection materials and a method for measuring protease using the above-described protease detection material are provided. A protease detection material, a set of protease detection materials, and a method of measuring protease which allow protease activity to be measured promptly with high sensitivity, and that allow, at the same time, morphological observation of tissues and cells on a thin film to be performed easily.10-01-2009
20090136980CD10-activated prodrug compounds - The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing the prodrug are also disclosed.05-28-2009
20130130294NOVEL METHOD FOR CHARACTERIZING AND MULTI-DIMENSIONALLY REPRESENTING THE FOLDING PROCESS OF PROTEINS - The invention relates to a novel method for characterizing and multi-dimensionally representing the folding process of proteins (FIG. 05-23-2013
20110111443APPARATUS FOR AUTO-PRETREATING SUGAR CHAIN - To provide an autoanalyzer for analyzing a sugar chain contained in a biological sample, in particular, serum. Namely, it is intended to provide a method of analyzing a sugar chain in a sample, which comprises the following steps: A) the sugar chain-releasing step of releasing the sugar chain in the sample; B) the detection sample-preparing step of preparing the released sugar chain for detection; and, in the case of conducting mass spectrometry using a plate, C) the step of forming a plate for the mass spectrometry having the captured sugar chain dotted thereon which comprises the step of providing the tagged sugar chain sample solution obtained in the step B) on a collection plate; and, if required, the step of conducting an operation in a solid phase support-enclosed plate to form the plate for mass spectrometry; and D) the step of analyzing the sugar chain to be assayed.05-12-2011
20090068698PREGNANCY-RELATED ENZYME ACTIVITY - This invention relates to the role of the enzyme proprotein convertase 5/6 in pregnancy, and in particular to the detection or modulation of proprotein convertase 5/6 and its isoforms in the uterus. This enzyme is useful in the control of fertility, the monitoring of early pregnancy, and for the detection of uterine receptivity. The invention also relates to methods of screening for compounds which have the ability to modulate the activity or expression of proprotein convertase 5/6, which may be useful in regulating fertility in mammals. Novel forms of proprotein convertase 5/6 are also disclosed and claimed.03-12-2009
20090142787Albumin Denaturing Agent - An albumin denaturing agent for digesting an albumin by a protease efficiently is provided. The albumin denaturing agent contains quaternary ammonium having a hydrocarbon group with a carbon number of 12 or more, or a salt of the quaternary ammonium. The albumin in a sample is digested by the protease in the presence of the albumin denaturing agent, a glycated part of the thus obtained albumin digestion product and a FAOD effect a reaction, and a redox reaction between the glycated part and the FAOD is measured, thereby determining a ratio (GA (%)) of the glycated albumin of the glycated albumin with respect to the albumin.06-04-2009
20110039289FLUOROGENIC PEPTIDES AND THEIR METHOD OF PRODUCTION - A method of making a fluorogenic peptide with an acridone fluorophor is provided, the method comprising the steps of: (a) providing an acridone derivative, said acridone derivative having first and second reactive groups (or precursors thereof), (b) providing a solid phase support provided with reactive species for reacting with the first reactive group of the acridone derivative (c) causing the solid phase support and acridone derivative to react so that the acridone derivative is attached to the solid phase support (d) providing the peptide or reagents for the formation of the peptide, and (e) subsequent to step (c), causing the reaction of the second acridone reactive group with the peptide or one or more of the reagents for the formation of the peptide.02-17-2011
20110111444Method of Screening for Compounds which Affect the Processing of EphA4 by Gamma-Secretase - The present invention provides a method of screening for compounds which affect the processing of EphA4 by γ-secretase, comprising the following steps: (i) contacting a first biological composition containing γ-secretase or a biologically active fragment thereof with a second biological composition containing EphA4 in the presence and absence of a candidate compound; (ii) measuring the cleavage of the EphA4 in the presence and absence of the candidate compound; (iii) selecting those candidate compounds which affect the cleavage of the EphA4 by γ-secretase; and (iv) identifying the candidate compounds selected in step (iii) as compounds which affect the processing of EphA4 by γ-secretase.05-12-2011
20110045518YKL-40 AS A GENERAL MARKER FOR NON-SPECIFIC DISEASE - The present invention relates to methods of diagnosing the presence of a non-specific disease or disorder in a subject, wherein a determined level of YKL-40 above a reference level indicates the presence of a non-specific disease or disorder. The subject may suffer from a variety of diseases or disorders. The reference level may be a reference level obtained from healthy individuals or it may be a previous measurement obtained from the same subject. The present invention furthermore relates to a method for classifying the severity of a non-specific disease or disorder in a subject, wherein a determined level of YKL-40 above or below one or more reference levels gives the severity of said non-specific disease or disorder. The present invention further relates to a kit and a device that may be used in the method of the present invention comprising means for measuring the level of YKL-40 in a sample; and means for comparing the measured level of YKL-40 with at least one reference level of YKL-40.02-24-2011
20090075318USING PHOTO-RESPONSIVE SURFACTANTS TO REVERSIBLY CONTROL PROTEIN AGGREGATION WITH LIGHT ILLUMINATION - The present invention relates to methods of inducing protein folding using light illumination. More specifically the invention relates to shape-reconstruction analysis applied to small angle neutron scattering (SANS) data that is used to determine the structure of partially-folded proteins in non-native conformations and supramolecular complexes undergoing self- or hetero-association in solution as a result of partial unfolding with a photoresponsive surfactant.03-19-2009
20090311732ANALYTICAL METHOD FOR ANALYZING C-TERMINUS TRUNCATION - This invention relates to analytical methods for quantification of truncation at the C-terminus of an Fc-containing protein.12-17-2009
20100055727FRET PROTEASE ASSAYS FOR BOTULINUM SEROTYPE A/E TOXINS - The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.03-04-2010
20110097758Peptide Conjugates and Fluorescence Detection Methods for Intracellular Caspase Assay - Polypeptides labelled with a donor and acceptor pair of dyes selected from a dibenzorhodamine dye and a diamino-benzophenoxazine dye are peptide conjugates which are useful for intracellular and bead-based assays with fluorescence detection. Peptide conjugates with a caspase-recognition site undergo cleavage into peptide fragments which may be detected, located, and quantitated by the changes in fluorescence. Intracellular cleavage of peptide conjugates is correlated with apoptosis.04-28-2011
20110151493POLYPEPTIDE DISULFIDE BOND ANALYSIS - The present invention relates in part to methods for determining bonding patterns in disulfide-linked peptides containing closely-spaced cysteine residues. Through N-terminal sequencing chemistry coupled with facile liquid chromatography and mass spectrometric analysis of the cleavage products, one can assign connectivity to specific cysteine pairs. A particular advantage of this method is maintenance of disulfide integrity during the process.06-23-2011
20090215101HCV Protease substrates - The present invention features HCV NS3 protease substrates containing a europium label and a quenching group. The europium label and quenching group are located on different sides of an ester HCV NS3 protease cleavage site. The substrate can be used in a time-resolved fluorescence (TRF) assay to measure HCV protease activity.08-27-2009
20110097757Biomarkers for Diabetes, Obesity, and/or Hypertension - Methods of identifying subjects having, or at risk of developing, diabetes, obesity, and/or hypertension are disclosed, as well as methods of identifying biomarkers for diabetes, obesity, and/or hypertension, and biomarkers identified by such methods.04-28-2011
20110076709Method for the Diagnosis of Leukemia Using Caspase-3 - The invention provides methods for determining the prognosis of a patient diagnosed with a leukemia, including B-cell chronic lymphocytic leukemia and acute myelogenous leukemia, by measuring the level of caspase-3 activity in a biological sample. The invention also relates to the diagnosis of leukemia, including B-cell chronic lymphocytic leukemia and acute myelogenous leukemia.03-31-2011
20120034638Electrochemical assay for the detection of enzymatically active PSA - The present invention is directed to the diagnosis of cancer associated with enzymatically active PSA in samples.02-09-2012
20100311097STABLE ISOTOPE LABELED POLYPEPTIDE STANDARDS FOR PROTEIN QUANTITATION - This invention relates to proteins having an amino acid sequence containing several amino acid subsequences found in nature and wherein at least two different subsequences act as monitor sequences, said subsequences being part of at least one natural protein which is a target protein, wherein the end of each of said two different subsequences have a cleavage site that will be cleaved by the same site-specific proteolytic treatment to release said subsequences.12-09-2010
20100081157FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS - The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.04-01-2010
20110151494METHODS AND MATERIALS FOR MONITORING MYELOMA USING QUANTITATIVE MASS SPECTROMETRY - The subject invention concerns methods and materials for diagnosing, monitoring the progress, and/or providing a prognosis for multiple myeloma and other conditions associated with antibody production in a person or animal. The methods o f the invention utilize mass spectrometry for quantitative monitoring and detection of antibody produced by the plasma cells. The methods of the invention can be utilized for diagnosis, monitoring, and/or prognosis of multiple myeloma, monoclonal gammopathy, and other immunological or hematological conditions and disorders. In addition to detecting and quantifying antibody in a sample, other biological markers, such as serum albumin and/or beta-2-microglobulin, can also be detected and quantified using the present invention, and in combination with detection and quantification of antibody. Thus, in one embodiment, both antibody and serum albumin and/or beta-2-microglobulin are detected and quantified using mass spectrometry and a diagnosis or prognosis made based on the results and levels detected.06-23-2011
20080213815DIAGNOSING BREAST CANCER BY SEPRASE LEVEL - A method of diagnosing subjects for breast cancer comprising the steps of (a) establishing the seprase level of a subjects test material and (b) determining those subjects with seprase levels above about 0.0008 nmoles.min09-04-2008
20110256567FLUORESCENT CYCLIC PEPTIDES, PREPARATION METHOD THEREOF AND USE OF THESE PEPTIDES FOR MEASURING THE ENZYMATIC ACTIVITY OF A PROTEASE ENZYME - The invention pertains to a cyclic peptide comprising the following sequence:10-20-2011
20100311098METHOD FOR DETERMINING THE AMINO ACID SEQUENCE OF PEPTIDES - The invention is in the field of analytical methods suitable for biochemical applications and provides a method for determining the amino acid sequence of a peptide. The determination of amino acid sequences of proteins and peptides is useful in the study of biological systems. The invention relates to a method for determining at least part of the amino acid sequence of a protein comprising the steps of cleaving the protein into proteolytic peptides, ionizing the proteolytic peptides to generate peptide precursor ions, dissociating these peptide precursor ions using tandem mass spectrometry in order to obtain peptide fragment ions, followed by determining the amino acid sequence of a selected proteolytic peptide wherein the cleaving step generates at least one proteolytic peptide with an N-terminal lysine residue and wherein the dissociation of the peptide precursor ions is initiated by electron transfer.12-09-2010
20080254493Screening Method Identifying Protease Secretion-Deficient Mutants of Microorganisms - The invention relates to a method for identifying a protease secretion deficient strain of a microorganism, wherein: 10-16-2008
20120202235NOVEL FRUCTOSYL PEPTIDYL OXIDASE - In one form, a fructosyl peptidyl oxidase derived from a budding yeast 08-09-2012
20110020854Enhancing Endotoxin Detection - Provided herein are methods for detecting gram negative bacteria or lipopolysaccharide in a sample. Kits for detecting gram negative bacteria or lipopolysaccharide in a sample are provided.01-27-2011
20110053197UBIQUITIN PROTEASOME SYSTEM PROFILING AND THE USE THEREOF IN CLINICAL APPLICATIONS FOR CANCER DIAGNOSIS - Provided herein are methods for the diagnosis, prognosis, or management of neoplastic diseases, i.e. cancer, and other diseases using profiles of the ubiquitin-proteasome system determined from acellular body fluids or cell-containing samples. Further provided are methods of predicting response to therapy in certain populations of cancer patients.03-03-2011
20110053196METHOD FOR MODIFYING A PEPTIDE AND A METHOD FOR IDENTIFYING A PEPTIDE - The present invention is to provide a method for easily and specifically modifying specific amino acid residue(s) constituting a peptide and to provide a methodology of improving the accuracy of identification of the peptide using a new information of the peptide obtained from the number of modified amino acid residue by said specific modification method as mentioned. The method for modifying a peptide according to the present invention is characterized:03-03-2011
20110136160ANALYSIS OF GLYCATED PROTEINS - This invention relates to a method for analysis of one or more glycated proteins in a sample, the glycated proteins containing moieties of a natural reducing carbohydrate bound at one or more glycation sites in the proteins, the method comprising: treating the sample with a stable isotopic form of said carbohydrate which is different in mass from the natural carbohydrate, whereby the isotopic form becomes incorporated by glycation in one or more proteins in the sample, and one or more of said proteins are accordingly glycated by the natural reducing carbohydrate and by the isotopic form of the carbohydrate at identical glycation sites; and identifying and/or quantifying the glycated proteins by the difference in mass between the natural carbohydrate and the isotopic form of the carbohydrate at identical glycation sites.06-09-2011
20100173341APOPTOSIS-BASED EVALUATION OF CHEMOSENSITIVITY IN CANCER PATIENTS - Induction of apoptosis in target cells is a key mechanism by which chemotherapy induces cell killing. An in vitro system has been established for determining carboplatin and paclitaxel (Taxol) chemosensitivity of epithelial ovarian cancer cells, where measurements of caspase-3 activation are surrogate markers for activation of chemotherapy-induced programmed cell death. To validate the assay as a predictor of clinical chemotherapy-induced programmed cell death. To validate the assay as a predictor of clinical chemosensitivity in vitro apoptotic response were compared to the clinical response of the patients from whom the tumor cells were isolated. Caspase-3 activation in response to in vitro chemotherapy to both drugs was shown to have an 83% positive predictive value and a 71% negative predictive value. Markers of apoptosis such as caspase-3 activation can be quantitated and utilized to predict the clinical response to chemotherapy.07-08-2010
20100216177METHOD AND KIT FOR UNIVERSAL VERIFICATION OF ENZYME ACTIVITY AND PROTEIN DIGESTION - A method of assessing enzyme function or protein stability is disclosed. A sample having a protein therein is contacted with an enzyme that is suspected of being capable of catalyzing digestion of the protein in order to form a mixture. First and second aliquots are removed from the mixture at first and second times, respectively, and protein digestion is evaluated using a detection reagent to calculate a change in absorbance between first and second aliquots. The change in absorbance provides an index of enzyme activity, enzyme capability, and protein stability.08-26-2010
20090203058Method for determination of allergen in environment and kit for simple quantification of allergen - A simple method for measuring allergens is disclosed, by which the amount of environmental allergens can be measured simply without using an anti-allergen antibody. In the method for measuring an environmental biological allergen(s), a solution containing a substrate of a protease which the allergen(s) has (have) is brought into contact with a test sample collected by using an adhesive sheet, which substrate gives a visible color change as a result of an enzyme reaction; and measuring the protease activity in the test sample using the color change of the substrate solution as an index, thereby measuring the biological allergen(s).08-13-2009
20120309042DIAGNOSTIC ORAL DEVICE - Described herein are devices and methods for identifying the existence of an oral condition in a subject.12-06-2012
20120309041Determination of Exosomel Biomarkers for Predicting Cardiovascular Events - The present invention relates to a method of predicting the risk of a subject developing a cardiovascular event, comprising determining the presence of a biomarker that is indicative of the risk of developing a cardiovascular event in exosomes from the subject. The exosomes are suitably isolated from a body fluid selected from serum, plasma, blood, urine, amniotic fluid, malignant ascites, bronchoalveolar lavage fluid, synovial fluid, breast milk, saliva, in particular serum. The biomarker is selected from the proteins Vitronectin, Serpin F2, CD14, Cystatin C, Plasminogen, Nidogen 2 or any combination of two or more of these proteins.12-06-2012
20110189712METHODS FOR ASSAYING PERCENTAGE OF GLYCATED HEMOGLOBIN - The invention provides enzymatic methods for direct determination of percentage of glycated hemoglobin in blood samples without the need of a separated measurement of total hemoglobin content in blood samples. The methods utilizes one or two different types of oxidizing agents which selectively oxidize low-molecular weight reducing substances and high-molecular weight (mainly hemoglobin) reducing substances in blood samples, coupled with enzymatic reactions catalyzed by proteases, fructosyl amino acid oxidase, and peroxidase. The invention provides kits for performing the methods of the invention.08-04-2011
20110262945GLYCOPROTEIN PRODUCTION METHOD AND SCREENING METHOD - A method for producing a glycoprotein, which is uniform in terms of functions derived from a sugar chain (e.g., a blood half-life) and physiological activities, i.e., a glycoprotein, which is uniform in terms of the amino acid sequence, the sugar chain structure and the higher-order structure; specifically, a method for producing a glycoprotein, which is uniform in terms of the amino acid sequence, the sugar chain structure, and the higher-order structure, includes the following steps (a) to (c): (a) folding a glycoprotein, which is uniform in terms of the amino acid sequence and the sugar chain structure; (b) fractionating the folded glycoprotein by column chromatography; and (c) collecting a fraction having a specified activity.10-27-2011
20110262947Isotopically-Labeled Proteome Standards - The invention provides methods for quantifying biomolecules, such as polypeptides in mass spectrometric analysis. The methods include use of a biomolecule standard having at least one atomic isotope different than that of the naturally occurring isotopes in the biomolecule of interest. Methods of the present invention also include methods for quantifying biomolecules where the copy biomolecule standard is made by expressing the biomolecule using a recombinant cell. Further included are the biomolecule standards themselves, method for making such standards, kits, systems, reagents, and engineered cells relating to the use of biomolecule standards in mass spectrometric analysis.10-27-2011
20110008811Resin Assisted Capture of Cysteine-Modified Proteins/Peptides and Determination of Presence and Location of Modification - A resin connected by amide bond to pyridyl sulfide or methylthiosulfonate can be conjugated to a post traditionally modified protein/peptide to allow determination of presence and kind and optionally location of cysteine modification(s).01-13-2011
20100323381CLASSIFYING AMYLOIDOSIS - This document provides methods and materials related to determining the identity of amyloid polypeptides in biological samples. For examples, methods and materials for identifying an amyloid polypeptide present in a fat aspirate are provided herein.12-23-2010
20120040389METHOD FOR DEMONSTRATION OF A MOLECULAR EVENT IN A CELL BY MEANS OF FLUORESCENT MARKER PROTEINS - The invention relates to a method for demonstration of the occurrence of a molecular event, particularly in a cell, characterised by the detection of the ‘solubilisation’ of a fixed protein marker (or the fixing of a solubilised protein marker) which is a direct or indirect marker for the occurrence of the particular molecular event. Said protein marker is present in the cell before the above detection, the cell being subjected to a permeabilisation of the plasma membrane before detection, which liberates the solubilised protein into the extracellular medium, the presence of the marker protein thus being detected in the cell or the extra-cellular medium by any appropriate means, which permits the detection of whether the solubilisation, or the fixing have taken place and, hence, the corresponding molecular event.02-16-2012
20100330599INHIBITORS OF USP1 DEUBIQUITINATING ENZYME COMPLEX - The invention provides compositions and methods used to inhibit USP1 deubiquitinase activity and to identify new inhibitors of USP1 deubiquitinase. The inhibitors can be used to treat or prevent cancer, bone marrow failure, and damage to cells or DNA resulting from genotoxic agents such as antineoplasic agents, including chemotherapeutic agents and radiation. The inhibitors include siRNA directed at inhibiting the expression of USP1 or UAF1, a protein which forms a heterodimeric complex with USP1. The inhibitors can be used to enhance cell survival if administered either before or after radiation exposure. Methods are also provided to enhance chemotherapy or radiotherapy of cancer and to enhance DNA repair. Transgenic knockout animals and knockdown cells are provided, whose USP1 expression is impaired.12-30-2010
20090042229PLATELET BIOMARKERS FOR CANCER - The present invention relates to the fields of immunology and biochemistry. Particularly, the present invention describes methods, devices and kits for early detection of clinical conditions having associated changes in systemic angiogenic activity, particularly cancers, inflammatory conditions, infections, and events associated with pregnancy and abortion.02-12-2009
20090258382Novel devices for the detection of the presence and/or activity of proteases in biological samples - The subject invention provides novel devices and methods for the detection of the presence and/or activity of proteases in biological samples.10-15-2009
20090162882Methods for determining proteins and protein-bound compounds comprising enzymatic modification - The present invention relates to a method for quantifying a non-proteinaceous corn pound bound to one or more carrier proteins in a sample comprising the steps of: i) separating complexes of said non-proteinaceous compound bound to said one or more carrier proteins from the non-proteinaceous compound that is not bound to said one or more carrier proteins; ii) releasing the non-proteinaceous compound from said one or more carrier proteins by treating the complexes of (i) with one or more enzymes; and iii) quantifying the non-proteinaceous compound enzymatically released in step (ii). In a preferred embodiment, the non-proteinaceous compound is cobalamin or an analogue thereof, and the carrier protein is transcobalamin or haptocorrin. The invention further relates to a method for quantifying a glycoprotein in a sample comprising the steps of: i) treating a sample with deglycosylating enzyme; and quantifying said glycoprotein. In a preferred embodiment, said glycoprotein is haptocorrin.06-25-2009
20120309039NON-FRET BOTULINUM ASSAY - A composition includes an artificial construct having (a) a reporter-containing portion chemically coupled to (b) a cleavage site. The cleavage site interacts with an investigational substance in a manner that cleaves the reporter-containing portion from a remainder of the construct. The cleaved portion is destroyed or otherwise degraded by the local environment, and presence of an investigational substance is evidenced by reduction in signal from the reporter. The investigational substance is preferably a Botulinum toxin (BoTN), and the cleavage sequence is all or part of a SNARE protein. The cleavable reporter-containing portion is preferably Yellow Fluorescent Protein (YFP), Citrine, Venus, or a YPet protein.12-06-2012
20120064558Assays for Differentiating between Ischemic and Hemorrhagic Stroke in a Human Patient - Methods are disclosed for rapidly and reliably differentiating between ischemic and hemorrhagic stroke events in a human patient. The methods include obtaining a biological sample, such as blood serum, and analyzing the sample or a derivative thereof by mass spectrometry to measure the amount of one or more targeted proteins differentially present and ischemic and hemorrhagic stroke patients. The analysis may include proteolytic digestion of the biological sample and selective reaction monitoring (SRM) tandem mass spectrometry of the digested sample to determine the amounts of surrogate peptides corresponding to the targeted proteins.03-15-2012
20120156709Electrochemical Assay for the Detection of Enzymes - The invention relates to novel compositions and methods for the detection of enzymes using the nuclear reorganization energy, λ, of an electron transfer process.06-21-2012
20120156707PROTEOME ANALYSIS IN MASS SPECTROMETERS CONTAINING RF ION TRAPS - A complex protein mixture is analyzed by jointly digesting the mixture, separating the digest peptides chromatographically or electrophoretically, and ionizing the digest peptides eluting from the separation device by an ionizing method that generates multiply charged ions. Digest peptide ions within a pre-selected range of m/z-values are isolated in an RF ion trap and subsequently reduced in their charge state. The charge-reduced ions can be measured with very high sensitivity. By repeating this process with adjacent isolation mass windows within the time duration of each separation peak, it is possible to determine the masses m, the prevalent charge states z, the retention times t, and the intensities i of a huge number of digest peptides of the complex protein mixture in a single separation run.06-21-2012
20090317851HEMOGLOBIN A1C DETERMINATION METHOD, ENZYME TO BE USED THEREFOR, AND PRODUCTION METHOD THEREOF - There is provided a method for specifically determining a glycated β-chain N-terminal of glycated hemoglobin using enzymes without a separation operation, and a determination reagent kit therefor. A protease that cleaves a glycated amino acid and/or a glycated peptide from a glycated β-chain N-terminal without substantially cleaving a glycated amino acid or a glycated peptide from a glycated α-chain N-terminal of glycated hemoglobin or a fragment thereof is screened. The method of specifically determining a glycated β-chain N-terminal of glycated hemoglobin and the determination reagent kit are provided by using the protease obtained by the screening method. According to the present invention, a glycated β-chain N-terminal of glycated hemoglobin can specifically be determined without a separation operation.12-24-2009
20120309040DETECTION OF OXIDIZED POLYPEPTIDES - A diagnostic method for determining the absence or presence of a disease is provided. The method generally includes assaying the amount and/or types of oxidized peptides in a sample from a subject, and comparing these to the amount and types of reference oxidized polypeptides. The method may include the use of stable isotope label, affinity selection, to identify and quantify changes in oxidized peptides or oxidized proteins associated with diseases such as type II diabetes mellitus, breast cancer, and Parkinson's disease, to monitor a patient's response to a therapeutic agent (e.g., an antioxidant), and/or to monitor disease recurrence.12-06-2012
20110318770COMPOSITIONS, KITS AND METHODS FOR DETERMINING PLASMIN ACTIVITY - Compositions, kits, and methods for determining plasmin activity using a fluorogenic peptide substrate are provided.12-29-2011
20100261214Method for Determining ACE2 Activity - The present invention relates to a method of determining ACE2 activity, comprising the following steps: providing ACE2-binding units immobilized on a solid carrier and specific for a part of ACE2 which is not involved in the catalytic activity of ACE2; contacting the immobilized ACE2-binding units with a sample which potentially includes the ACE2, wherein the ACE2 is bound by the ACE2-binding unit; removing the non-binding portions of the sample from the ACE2 bound to the ACE2-binding units; adding a substrate of the ACE2 which is reacted by the ACE2 activity, with the reaction providing a signal; and measuring the change in the signal during a specific period of time, wherein the change can be correlated with the ACE2 activity.10-14-2010
20120003678NOVEL FRUCTOSYL PEPTIDE OXIDASE - A protein described in any one of [1] to [4] below is provided according to the present invention: 01-05-2012
20090047699FLUOROGENIC ENZYME ACTIVITY ASSAY METHODS AND COMPOSITIONS USING FRAGMENTABLE LINKERS - Substrate compound-containing micelles and various compositions, kits and methods for their preparation and use are provided.02-19-2009
20120009614THYROGLOBULIN QUANTITATION BY MASS SPECTROMETRY - Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.01-12-2012
20100015652ANTIBODY QUANTITATION - The invention relates to a novel method for determining the amount of an antibody of interest in a biological sample. In one embodiment, the method of the invention is characterized in that it comprises at least a step of protein depletion of said biological sample by pepsin digestion to produce F(ab)01-21-2010
20110165607METHOD FOR EVALUATING STATUS OF SKIN BARRIER FUNCTION OF NATURAL MOISTURIZING FACTOR USING BLEOMYCIN HYDROLASE ACTIVITY AS INDICATOR - The present invention provides a method for evaluating the status of the skin barrier function of natural moisturizing factor (NMF) using the activity of bleomycin hydrolase in skin tissue as an indicator.07-07-2011
20120058502Method for Identifying Protease Inhibitors - The invention describes a method for assaying HCV NS3 protease activity using an NS3•4A protease molecule. The invention also provides a method for screening and identifying modulators of NS3 protease.03-08-2012
20100124757GOLD NANOPARTICLE BASED PROTEASE IMAGING PROBES AND USE THEREOF - Disclosed are a metal nanoparticle onto which a peptide substrate specifically degraded by protease and fluorophore are chemically modified for selectively imaging protease expressed in cell and in tissue in a human body, and the use thereof. Also, a quantitative analysis method of protease using the metal nanoparticle, a cell imaging method and a drug screening method of inhibiting a protease overexpression are provided. In detail, the present invention is directed to a metal nanoparticle having a peptide substrate and fluorophore coupled thereto, the peptide substrate and the fluorophore being specifically degraded by due to a protease activated in various ways in cell and in a human body to exhibit fluorescence. Hence, the metal nanoparticle can be used to rapidly screen activation and inhibition of the protease in the imaging manner. Also, the metal nanoparticle is capable of being selectively absorbed into a cell and a tissue so as to be possibly used as a sensor for real-time cell imaging and early diagnosis of non-invasive diseases.05-20-2010
20120208224NOVEL METHOD FOR QUANTIFYING PROTEINS BY MASS SPECTROMETRY - The present invention relates to a method for the quantitative detection of a target protein in a sample, in which the second-generation fragment ions are detected for providing a series of quantitative measurements, at least one of which is correlated to the amount of proteotypic peptide generated and to the amount of target protein in the sample, characterized in that the selected first-generation fragment ion having a mass (m/z)08-16-2012
20120107855CROSSLINKING REAGENT FOR ANALYSIS OF PROTEIN-PROTEIN INTERACTION - Crosslinking reagents and methods for using the same for analysis of protein-protein interactions, are provided. The crosslinking reagents include a trifunctional scaffold that links two protein linking groups to each other and branches to link an affinity tag, where the protein linking groups can be fragmented from the scaffold. The distance between the two protein linking groups can be selected to crosslink two proteins of a protein complex via accessible amino acid residues. Also provided are crosslinked polypeptide compounds and kits that include crosslinking reagents. These reagents and methods find use in a variety of applications in which crosslinking of proteins in desired.05-03-2012
20120156710METHOD FOR QUANTIFYING PROTEIN - The present invention provides a method that is useful for measuring the absolute amount of a target protein contained in a protein mixture, such as a biological sample. The method of the present invention includes the steps of: 06-21-2012
20120156708Method For Simultaneously Determining Multiple Coagulation Proteases - The present invention relates to a chromogenic method for simultaneously determining the activity of multiple coagulation proteases or for simultaneously determining the inhibition of multiple coagulation proteases in a single test reaction. For this purpose, use is made of two chromogenic substrates which have different absorption maxima and whose color signals can be separated spectrally.06-21-2012
20090215102Method to Assess Breast Cancer Risk - We show that urinary metalloproteinases (MMP's) (e.g. MMP 9) and a disintegrin and metalloprotease 12 (ADAM 12) are significantly elevated in women at high risk for developing breast cancer and that monitoring for the absence or presence of both MMP 9 and ADAM 12 represents a new means for breast cancer risk assessment. In addition, we show that levels of MMP 9 and ADAM 12 serve as independent predictors of breast cancer risk. Furthermore, we have determined that elevated levels of urinary ADAM 12 predict an increased risk for breast cancer in subjects predicted not to be at risk for breast cancer by the Gail 5 -year risk model08-27-2009
20110065140PROGRAMMABLE ELECTROMAGNETIC ARRAY FOR MOLECULE TRANSPORT - An embodiment of the invention relates to a device comprising (1) an array of electromagnetic elements comprising coils, metal cores, and metal core heads, and (2) a controller that is adapted to control a current for one or more coils individually, to vary the current for said one or more coils individually, to reverse the current for one or more coils individually, and to generate a specific magnetic flux distribution and gradient across two or more coils; wherein the metal core head is at one end of the coil and the metal core head has a geometry to create a desired magnetic flux, intensity and gradient, in a region of interest between two adjacent coils; further wherein the device is functionally coupled to a fluidic device to concentrate and transport magnetic particles in a fluid without fluidic movement of the fluid.03-17-2011
20120122134Novel Peptidase Substrates - The present invention relates to the use of a compound of the following formula (I) for detecting a peptidase activity and/or a variation in pH:05-17-2012
20100093010Inhibitor for the Formation of Gamma-Secretase Complex - It is intended to provide an inhibitor for the formation of a γ-secretase complex which comprises a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator as the active ingredient; and use of a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator for producing the same. It is also intended to provide a method of screening a substance having an effect of inhibiting the formation of an active complex of γ-secretase which comprises assaying the activity of inhibiting cholesterol synthesis or quantifying cholesterol accumulated in lipid rafts in cells. It is also intended to provide a method of screening a cholesterol synthesis inhibitor, a protein geranylgeranylation regulator or an HMG-CoA reductase inhibitor which comprises assaying the effect of inhibiting the formation of an active complex of γ-secretase. Moreover, it is intended to provide a method of screening an effect of a test substance on γ-secretase which comprises measuring the distribution of constituents (niscastrin, APH-1, Pen-2 and so on) required by γ-secretase for the formation of its active complex in cells.04-15-2010
20130171676METHOD FOR MEASURING GLYCATED HEMOGLOBIN - It is to provide a method for measuring glycated hemoglobin in a hemoglobin-containing sample, comprising reacting the hemoglobin-containing sample with a proteolytic enzyme in the presence of a surfactant, and then reacting the obtained reaction product with fructosyl peptide oxidase, wherein at least one of the former reaction and the latter reaction is performed in the presence of an isothiazolinone derivative; and measuring the generated hydrogen peroxide. The present invention provides a method for accurately and highly sensitively measuring glycated hemoglobin in a hemoglobin-containing sample without being influenced by hemoglobin.07-04-2013
20120231486METHOD AND APPARATUS TO PERFORM HYDROGEN-DEUTERIUM EXCHANGE - Apparatus and methods to perform hydrogen/deuterium exchange using semipermeable membranes are described. The system has two channels separated by a semipermeable membrane. One channel comprises a flow carrying the analyte of interest, and the second channel comprises a solution comprising a deuterated solvent (e.g. deuterium oxide). The system does not require an external electric field gradient across the membrane to perform the hydrogen-deuterium exchange procedure. The present invention facilitates sample and reagent handling as well as simplifies manufacture of devices and/or instrumentation related to deuterium exchange.09-13-2012
20120129202COMPOSITION FOR ASSAYING GLYCATED PROTEINS - Compositions for accurately assaying a glycated protein by: 1) avoiding effects of globulin and ascorbic acid components, 2) stabilizing proteases and at least enzymes acting on glycated amino acids; 3) accurately assaying albumin; and 4) assaying glycated albumin while avoiding the effects of glycated hemoglobin, and an assay method are provided. Thus, the contents of a glycated protein and glycated albumin can be more accurately determined.05-24-2012
20120129201MASS SPECTROMETRY IMAGING WITH SUBSTANCE IDENTIFICATION - A method for the identification and localization of proteins or other biomolecules of a histologic tissue section comprises enzymatically digesting the biomolecules of two similar tissue sections while substantially preserving the biomolecule positions in the tissue sections. Next, a mass spectrometric image of the digest products in one of the tissue sections is acquired. Then, the digest products of the other tissue section are extracted and separated and the mass spectra and daughter ion spectra of all the digest products are acquired. A list of all identifiable biomolecules of the tissue section is created by comparing the mass spectra and daughter ion spectra with spectra in biomolecule structure databases or spectral libraries. Finally, the biomolecules in the list are assigned to digest products of the same mass in the mass spectra used to create the mass spectrometric image of the thin tissue section.05-24-2012
20120129203Novel Peptidase Substrates - The present invention relates to the use of a compound of the following formula (I) for detecting a peptidase activity and/or a variation in pH:05-24-2012
20120164675METHODS AND KIT FOR PROTEASE ENZYME ASSAYS - A method for testing efficacy of a protease enzyme assay, the method comprising providing an enzyme which acts as a surrogate enzyme control for the protease enzyme; combining the surrogate enzyme control with an assay substrate for the protease enzyme; and determining a change in the assay substrate resulting from the surrogate enzyme control acting on the assay substrate; wherein the protease enzyme is selected from the group consisting of metalloproteinases, serine proteases, and cysteine proteases; a method for conducting a protease enzyme assay using the method for testing efficacy; a kit including an enzyme which acts as a surrogate enzyme control for a protease enzyme in testing efficacy of a protease enzyme assay; and a method of releasing the kit are provided.06-28-2012
20120135444SAMPLING DEVICES AND METHODS OF USE - The present disclosure provides devices and rapid methods to acquire a wound sample to detect the presence of NO05-31-2012
20120135442PROTEIN CRYSTALLIZATION USING MOLECULARLY IMPRINTED POLYMERS - The invention relates to a method comprising: providing a molecularly imprinted polymer imprinted with a first peptide or protein; exposing said molecularly imprinted polymer to a supersaturated solution of a second peptide or protein; and forming a nucleus of and/or growing a crystal of said second peptide or protein on said molecularly imprinted polymer.05-31-2012
20120135443Rapid Bed-Side Measurement of Neutrophil Elastase Activity in Biological Fluids - The subject invention provides novel devices and methods for the detection and quantification of neutrophil elastase activity in biological samples.05-31-2012
20120135441ENZYMES AND METHODS FOR RESOLVING AMINO VINYL CYCLOPROPANE CARBOXYLIC ACID DERIVATIVES - Preparation and isolation of amino vinyl cyclopropane carboxylic acid derivatives and salts thereof, methods of resolving enantiomers, and methods of identifying compositions and/or enzymes that are capable of resolving racemic or partially enantiomerically enriched mixtures.05-31-2012
20120135440CATIONIC ANTI-MICROBIAL PEPTIDES AND METHODS OF USE THEREOF - Described herein are methods of detecting a wound infection and for detecting the presence or absence of microorganisms, for example, wound pathogens in a sample, by contacting a sample with a cationic anti-microbial peptide that is degradable by an enzyme produced and/or secreted by a microorganism, and detecting degradation or the absence of degradation of the peptide, as an indicator of the presence or absence of the enzyme in the sample, and thus indicative of the presence or absence of a microorganism in the sample. The present invention also features a biosensor for detecting the presence or absence of a microorganism in a sample.05-31-2012
20120171710Method for Grass Species Identification - The present invention relates to the use of at least one peptide comprising or consisting of a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, for determining the presence of extracts from at least one grass species in a composition.07-05-2012
20120171711NOVEL METHOD FOR ISOLATING TRICHINELLA OR OTHER PARASITES FROM ORGANIC TISSUE - The present invention relates to a method for the detection of essentially intact encapsulated or non-encapsulated parasites in meat, comprising the maceration of the meat with an alkaline digestion solution which contains a digestive enzyme that is active in an alkaline environment. Further, uses of a serine endopeptidase in a method for the detection of essentially intact encapsulated or non-encapsulated parasites in meat are described. The present invention also describes serine endopeptidases for use in a diagnostic method for the detection of essentially intact encapsulated or non-encapsulated parasites in meat. Finally, a kit is disclosed which comprises the enzymes and alkaline digestion solutions of the present invention.07-05-2012
20100047837METHOD FOR THE EARLY DETECTION OF RENAL INJURY - A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.02-25-2010
20120178118BIOMARKERS FOR MONITORING TREATMENT OF NEUROPSYCHIATRIC DISEASES - Methods for identifying and measuring pharmacodynamic biomarkers of neuropsychiatric disease, and for monitoring a subject's response to treatment.07-12-2012
20100273198ENGINEERING ENZYMATICALLY SUSCEPTIBLE PROTEINS - The invention provides a synthetic phytase polypeptide which encodes an enzymatically susceptible phytase. Also provided are feed or food products comprising an enzymatically susceptible phytase, and transgenic plants which express the enzymatically susceptible phytase. Further provided are methods for making and using enzymatically susceptible phytases, e.g., a method of using an enzymatically susceptible phytase in feed and food processing.10-28-2010
20100015651Predicting Heart Failure Following Myocardial Infarction by Protease and Protease Inhibitor Profiling - Disclosed herein are methods of detecting or predicting diastolic heart failure in a subject, comprising identifying a profile of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) from a body fluid of the subject that is associated herein with the existence of likely development of left ventricular dilation (LVD).01-21-2010
20100009398BIOLOGICAL REACTION APPARATUS WITH DRAINING MECHANISM - A biological reaction apparatus for receiving at least one substrate having a sample located in a sample region, and a separate cover, such that a reaction chamber is formed between the cover and substrate over the sample region, wherein the apparatus includes a locating means to locate the substrate; a cover locating means for locating and moving the cover with respect to the substrate; a fluid dispensing means for dispensing fluid into the reaction chamber; and a draining mechanism; wherein the draining mechanism includes wicking means.01-14-2010
20120264158ANIONIC ACID-LABILE SURFACTANTS AND METHODS OF USE - Anionic acid-labile surfactants may generally comprise compounds represented by the formula:10-18-2012
20120264156Method for Characterizing At Least One Microorganism By Means Of Mass Spectrometry - The present invention relates to a method for characterizing at least one microorganism from a sample, said method including identifying said at least one microorganism and determining the properties of typing, potential resistance to at least one antimicrobial, and virulence factor, characterized in that determining the properties of typing, resistance to at least one antimicrobial, and virulence factor for said at least one microorganism is implemented by means of mass spectrometry through the use of proteins, peptides and/or metabolites as markers of said properties of typing, resistance to at least one antimicrobial, and virulence factor.10-18-2012
20120264157ANIONIC ACID-LABILE SURFACTANTS AND METHODS OF USE - Anionic acid-labile surfactants may generally comprise compounds represented by the formula:10-18-2012
20120264155Multiplex Quantitation of Individual Recombinant Proteins in a Mixture by Signature Peptides and Mass Spectrometry - The present invention relates to an analytical method for quantitation of selected multiple recombinant proteins in a complex matrix such as recombinant polyclonal antibodies in serum or recombinant polyclonal antibodies expressed in a culture supernatant.10-18-2012
20120225444METHODS AND APPARATUS FOR FRACTIONATION-BASED CHEMICAL ANALYSES - A method for analyzing chemicals includes fractionating a complex sample into at least two sample portions that each include portions of two polypeptides though in different concentration ratios, digesting and performing LC/MS on each of the sample portions, and associating precursor ions observed via LC/MS with their corresponding polypeptide in response to LC/MS-provided intensity data. A set of precursor-ions that has substantially similar intensity ratios in both sample portions is determined to be associated with the same polypeptide.09-06-2012
20120083011Sensitive Methods for Detecting The Presence of Cancer - Described herein are sensitive methods for determining if a subject has cancer. The methods generally involve quantifying the amount of one or more biomarkers derived from Galectin-3 in a biological sample from the subject by mass spectrometry, wherein an increase in the amount of one or more biomarkers in the biological sample as compared to a control is an indication of the presence of cancer in the subject.04-05-2012
20120258484CANCER DIAGNOSIS MARKER USING THE ABERRANT GLYCOSYLATION OF A PROTEIN - The present invention relates to a method for diagnosing cancer using information on the aberrant glycosylation of a glycoprotein. More precisely, the present invention relates to a cancer diagnosis peptide marker, which is screened by: a step of separating, using a lectin, a glycoprotein which is aberrantly glycosylated in accordance with the occurrence of cancer; and a step of selecting a hydrolyzed peptide marker derived from the aberrantly glycosylated glycoprotein by observing the quantitative changes in the separated glycoprotein. The present invention also relates to a method for diagnosing cancer using the peptide marker as an agent.10-11-2012
20120258485METHOD FOR DETECTING AND QUANTIFYING A TARGET MOLECULE IN A SAMPLE - The invention relates to a method for identifying and quantifying by mass spectrometry at least one target molecule in a sample, comprising the following steps: 10-11-2012
20120258483METHOD FOR DETECTING A WOUND INFECTION - The present invention relates to a method for detecting a wound infection comprising the steps of: contacting a sample obtained from a wound with at least two substrates for at least two enzymes selected from the group consisting of lysozyme, elastase, cathepsin G and myeloperoxidase, and detecting a wound infection when a conversion of the at least two substrates with said at least two enzymes are determined.10-11-2012
20110124024Proteolysis Resistant Antibody Preparations - Antibody preparations with substantially homogeneous and unsialylated glycoforms, such as G0 and G2, are prepared by enzymatic treatment, expression under certain conditions, use of particular host cells, and contact with serum. These antibody preparations resist cleavage by proteases, such as papain, ficin, bromolein, pepsin, a matrix metalloproteinase, such as MMP-7, neutrophil elastase (HNE), stromelysin (MMP-3) and macrophage elastase (MMP-12), and glycosylation modification enzymes. The antibody preparations with substantially homogeneous and unsialylated glycoforms and methods of testing for glycosylation in an antibody are useful in connection with characterization of antibody properties and/or in diseases or conditions characterized by an increase in protease activity.05-26-2011
20080299597METHODS FOR ASSAYING PERCENTAGE OF GLYCATED HEMOGLOBIN - The invention provides enzymatic methods for direct determination of percentage of glycated hemoglobin in blood samples without the need of a separated measurement of total hemoglobin content in blood samples. The methods utilizes one or two different types of oxidizing agents which selectively oxidize low-molecular weight reducing substances and high-molecular weight (mainly hemoglobin) reducing substances in blood samples, coupled with enzymatic reactions catalyzed by proteases, fructosyl amino acid oxidase. The amount of hydrogen peroxide generated in the reaction is measured for determination of percentage of glycated hemoglobin in blood samples. The invention provides kits for performing the methods of the invention.12-04-2008
20080299596Substrates and assays for beta-secretase activity - The present invention is directed to novel substrates for Hu-Asp. More particularly, the invention provides peptide substrates and fusion polypeptide substrates comprising a β-secretase cleavage site. Methods and compositions for making and using the peptides are disclosed.12-04-2008
20120264154METHOD FOR QUANTIFYING BIOMOLECULES - The present invention relates to a method that allows comprehensive quantitation of one or a plurality biomolecules, including the entire complement of biomolecules in a sample by comparing their quantity to the quantity of reference biomolecules in a standard mixture obtained via extraction from at least two different cell populations. The invention further relates to said standard mixture itself, its preparation and use.10-18-2012
20120322094HIGH-MOLECULAR-WEIGHT ADIPONECTIN MEASUREMENT METHOD - Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin.12-20-2012
20120322092Resonance Energy Transfer Assay with Synaptobrevin Substrate Moiety - Compositions and methods for analyzing intracellular BoNT protease activity, and especially BoNT/B, BoNT/G, BoNT/D, and/or BoNT/F protease activity are provided. Most preferably, cells express one or more recombinant hybrid proteins that include one or more fluorescent proteins and at least one BoNT protease recognition and cleavage sequence, and analysis is performed using FRET analysis.12-20-2012
20120322093METHOD FOR THE DETERMINATION OF SEQUENCE VARIANTS OF POLYPEPTIDES - The current invention is directed to a method for determining amino acid sequence mutations in a produced polypeptide, comprising the following steps of a) providing a sample of a produced polypeptide, b) incubating the polypeptide in the sample with a protease, c) performing a two dimensional analysis using reversed phase chromatography coupled with a high resolution mass spectroscopy (FT-ICR/FT-orbitrap) and MS/MS analysis of the amino acid sequence fragments of the peptides, d) data evaluation by comparing the LC-MS data sets obtained for the samples side by side with the data set of a reference sample, by searching for differences in the signal intensities at given retention times and by evaluation of differential signals with respect to amino acid sequence mutations. The reference sample for data evaluation (d) can be either a well characterized standard or one of the samples to be analyzed.12-20-2012
20120270255METHODS FOR ISOLATING AND QUANTIFYING ANTIGEN FROM VACCINES - The disclosure relates to the development of improved methods for quantifying antigen in a vaccine composition in the absence of available antigen standards. More specifically, the disclosure provides fast and robust methods of separating antigens from vaccine compositions, comprising the steps of solubilizing antigen without detergent and without alkylation, using acidification to prevent antigen subtypes from binding again, isolating antigen subtypes with chromatography, and quantifying the eluted antigen with amino acid analysis. The methods of the disclosure are applicable for use with a variety of antigens, thereby providing an improved method in the art of vaccine manufacturing to date.10-25-2012
20120270254METHOD FOR ANALYZING SECRETOME, BIOMARKER FOR LUNG CANCER METASTASIS, AND SIRNA COMPOUND FOR INHIBITING LUNG CANCER METASTASIS - A method for analyzing secretome, a biomarker for lung cancer metastasis, and a siRNA compound for inhibiting lung cancer metastasis are disclosed. The method for analyzing secretome of the present invention comprises the following steps: (A) collecting proteome secreted from a cell; (B) providing a purification gel, wherein the purification gel comprises a low-density layer, and a high-density layer, and the low-density layer is stacked on the high-density layer; (C) adding the proteome on the low-density layer, and separating the proteome through the low-density layer and the high-density layer of the purification gel; (D) collecting the separated proteome on the interface between the low-density layer and high-density layer, and tagging the separated proteome with a reagent after digestion; and (E) analyzing the separated proteome tagged with the reagent, and comparing an analysis result with a proteomic database.10-25-2012
20100203566Methods for the Detection and Monitoring of Congestive Heart Failure - Disclosed herein are methods of detecting and/or prognosing congestive heart failure by detecting a proteolytic fragment of caspase-3 such as the p17 fragment or the p12 fragment. The congestive heart failure can be of any etiology, such as systolic or diastolic heart failure, ischemic or non-ischemic cardiomyopathy.08-12-2010
20100203565Peptide Fingerprint from the Degradation of Elastin by HNE - Methods for producing and using protein/peptide fingerprints, derived from elastin degraded by the enzyme human Neutrophil Elastase (HNE), allowing identification and investigation of disease-associated proteins/peptides that can be linked to specific drug targets, or to specific drug target combinations. The methods are particularly useful for studies relating to Chronic Obstructive Pulmonary Disease (COPD).08-12-2010
20110236917Diagnosis of Alzheimer's Disease - Embodiments of an assay for the screening, diagnosis, and differentiation of Alzheimer's disease uses selected sets of serum protein biomarkers. The assay is used to distinguish Alzheimer's disease from Parkinson's disease, other neurodegenerative diseases, and normal controls. Specific sets of serum protein biomarkers are identified for the diagnosis of Alzheimer's disease in drug naïve and drug treated patients.09-29-2011
20120276570Peptide Antibody Depletion and its Application to Mass Spectrometry Sample Preparation - The present invention relates, e.g., to a method for pre-processing a sample for mass spectral analysis, comprising cleaving proteins in the sample to peptides and immunodepleting highly abundant and/or well-ionizing and/or proteotypic peptides from the sample. Also described are methods for identifying well-ionizing peptides for use in this and other methods; analytic (diagnostic) methods using antibodies against highly ionizable peptides from a protein target of interest; and compositions, kits and devices comprising antibodies of the invention.11-01-2012
20110262946MONITORING A DYNAMIC SYSTEM BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY - The present invention provides a method for monitoring of profile changes of components in a dynamic system such as a cell-free in vitro protein synthesis system by using liquid chromatography (LC) combined with mass spectrometry (MS). In an additional aspect, this invention provides a method for enhancing the yield and/or reproducibility in a cell-free protein synthesis system by modulating the level and/or activity of a protein component that has regulatory effects on the system.10-27-2011
20120088260MASS SPECTROMETRY ASSAY FOR PLASMA-RENIN - Provided are methods for measuring renin activity in a plasma sample using mass spectrometry. The methods generally involve ionizing purified angiotensin 1 from the sample and detecting the amount of angiotensin 1 ions generated. The amount of detected angiotensin 1 ions are then related to the amount of angiotensin 1 generated in the sample, which in turn is related to renin activity in the sample.04-12-2012
20130183703ANALYTICAL METHOD FOR FAB AND FAB' MOLECULES - A method of measuring acidic species generated by degradation of a Fab or Fab′ component of a Fab-PEG or a Fab′-PEG comprising the steps of: a) cleaving the PEG and linker from the Fab-PEG or Fab′-PEG with an enzyme; b) optionally separating the PEG and linker generated in step a) from the Fab or Fab′, to provide a Fab or Fab′; and c) quantitatively analyzing acidic species associated with the cleaved Fab or Fab′ and/or the cleaved PEG.07-18-2013
20120288883PROBE REAGENT FOR MEASUREMENT OF PROTEOLYTIC ACTIVITY - This invention relates to a probe reagent comprising, in order from the N-terminus to the C-terminus, the amino acid sequences of a fluorescent protein I, a peptide capable of terminating protein degradation (i.e., a degradation-terminating peptide), a spacer peptide, a fluorescent protein II, and a protein to be degraded, wherein the protein to be degraded is a protein degraded by the ubiquitin-proteasome system, and the probe reagent is degraded from the C-terminus, but that the degradation of the probe reagent is terminated at the degradation-terminating peptide, a nucleic acid encoding the probe reagent, and use of the probe reagent or the nucleic acid.11-15-2012
20120100565HIGH PRESSURE ENZYMATIC DIGESTION SYSTEM FOR PROTEIN CHARACTERIZATION - A method and system for obtaining samples for proteomic analysis that utilizes pressure and a preselected agent to obtain a processing sample in a significantly shorter period of time than prior art methods and which maintains the integrity of the processing sample through the preparatory process. In one embodiment of the invention, a sample and an enzyme are combined and subjected to a pressure, preferably a pressure cycle range that varies between 0 to 35 kpsi, for a period of time of preferably less than 60 seconds. This process results in producing a sample suitable for analysis, which is preferably introduced to another analytical instrument such as a mass spectrometry instrument, or other device.04-26-2012
20120100564Prediction of Memapsin 2 Cleavage Sites - Aspartic proteases such as mempasin-2 are import enzymes, playing roles in a variety of diseases. The inventors have developed a model to predict the cleavage sites and preferences for memapsin 2 substrates.04-26-2012
20100209954METHOD OF IDENTIFICATION AND QUANTIFICATION OF PROTEINS, ISOFORMS OF THE ANGIOTENSIN I CONVERTING ENZYME, MOLECULAR GENETIC MARKER BASED ON SAID PROTEINS, USE OF MENTIONED MARKER, ANALYTICAL METHOD FOR DIAGNOSIS, RISK STRATIFICATION, THERAPEUTICAL DECISION IN CARRIERS OF ARTERIAL HYPERTENSION AND RENAL LESION AND KIT FOR USING IN THE DIAGNOSIE - A method of detecting a predisposition for the development of a kidney lesion in an individual including detecting a presence of at least three angiotensin converting enzyme isoforms in an aliquot of fresh or concentrated biological fluids, cells or tissues obtained from the individual; and quantifying the presence of the at least three antiotension converting enzyme isoforms.08-19-2010
20100184111MODIFIED TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME AND METHODS OF USE THEREOF - The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.07-22-2010
20100167326METHOD FOR CLEAVAGE OF PEPTIDIC BOND AT C TERMINAL OF PEPTIDE AND A METHOD FOR DETERMINATION OF C TERMINAL AMINO ACID SEQUENCE OF PEPTIDE - The present invention is to provide a method for cleavage of peptidic bond at C terminal of peptide and a method for determination of C terminal amino acid sequence of peptide without the decrease of the sensitivity and with preventing the subsidiary reaction. The method for cleavage of peptidic bond at C terminal of peptide according to the present invention is characterized as follows: 07-01-2010
20100167327System for obfuscating identity - Compositions, apparatus, systems, kits, and methods for obfuscating the nucleic acid and/or protein content of an environment.07-01-2010
20080254494Assays for measuring nucleic acid binding proteins and enzyme activities - Processes for measuring DNA or RNA binding proteins, specific nucleic acids, as well as enzyme activities using labeled nucleic acids of labeled protein/peptide molecules are provided.10-16-2008
20110269163METHOD AND MEDIUM FOR DETECTING THE PRESENCE OR ABSENCE OF STAPHYLOCOCCUS AUREUS IN A TEST SAMPLE - A presence/absence test for 11-03-2011
20130171677RECOMBINANT PHYCOBILIPROTEINS WITH ENHANCED FLUORESCENCE AND PHOTOCHEMICAL PROPERTIES - Novel fluorescent phycobiliprotein fusion proteins and methods of use are described. The novel phycobiliproteins can be produced in a cell comprising two or more heterodimeric lyases, an apoprotein and a bilin reductase, which components react to form the phycobiliprotein fusion protein. Also described are phycobiliprotein based transcription reporter cells and assays, which cells conditionally express a heterologous, fluorescent, phycobiliprotein domain even in anoxic conditions.07-04-2013
20130095514Method for Determining the Concentration of a Peptide - The present invention is related to a method for preparing an internal peptide standard, comprising a) providing a first tag, and b) coupling of a first peptide to the first tag, whereby the first peptide comprises an amino acid sequence, or a) providing a first tag and b) coupling to the first tag the amino acids forming the first peptide comprising an amino acid sequence, whereby the C-terminal end of the amino acid sequence of the first peptide corresponds to the C-terminal end generated by a sequence-specific hydrolysis of an amide bond, ester bond or thioester bond preferably of an amide bond of a peptide.04-18-2013
20130095513Resonance Energy Transfer Assay with Cleavage Sequence and Spacer - A molecular construct comprises a donor label, an acceptor label, a linker peptide disposed between the donor and the acceptor, the linker having a cleavage site sequence, and a spacer between at least one of (a) the donor and the cleavage site sequence and (b) the acceptor and the cleavage site sequence. Preferably, the construct is selected from the group consisting of CFP-(SGLRSRA)-SNAP-25-(SNS)-YFP, and CFP-(SGLRSRA)-synaptobrevin-(SNS)-YFP. In preferred embodiments, the linker peptide is a substrate of a botulinum neurotoxin selected from the group consisting of synaptobrevin (VAMP), syntaxin and SNAP-25, or a fragment thereof that can be recognized and cleaved by the botulinum neurotoxin. Advantageously, the spacer increases the electronic coupling between the donor label and the acceptor label relative to a corresponding construct without the spacer.04-18-2013
20130115645FGL-2 PROTHROMBINASE AS A DIAGNOSTIC TOOL FOR MALIGNANCY - The present: invention reveals a strong correlation between FGL-2 prothrombinase activity levels and the presence of a malignant proliferative disorder in a subject. Thus, the present invention provides FGL-2 prothrombinase activity as a diagnostic tool for malignancy.05-09-2013
20090075317METHODS AND COMPOSITIONS FOR MODULATING HEPATOCYTE GROWTH FACTOR ACTIVATION - The invention provides methods and compositions for modulating hepsin activity and the HGF/c-met signaling pathway, in particular by regulating pro-HGF activation by hepsin.03-19-2009
20080199897CLASS II HISTONE DEACETYLASE WHOLE CELL ENZYME ASSAY - The invention relates to enzymatic assays and substrates for Class II histone deacetylases. More particularly, the invention relates to such assays and substrates utilizing whole cells, extracts of such whole cells, extracts of sub-cellular compartments of such whole cells, or bodily fluids.08-21-2008
20130203096Selected Reaction Monitoring Assays - Provided herein are methods for developing selected reaction monitoring mass spectrometry (LC-SRM-MS) assays.08-08-2013
20130203097SUBSTRATES THE FLUORESCENCE OF WHICH IS SUPPRESSED, PREPARATION THEREOF, AND USE THEREOF FOR IDENTIFYING, DETECTING, AND ASSAYING LEGIONELLA PNEUMOPHILIA - The present disclosure includes the use of an R—(X)08-08-2013
20130203099THYROGLOBULIN QUANTITATION BY MASS SPECTROMETRY - Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.08-08-2013
20110229921METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS - A method of prognosticating cadaveric kidney transplant function in a patient; a method of prognosticating cadaveric kidney transplant function in a patient diagnosed with DGF; a method of assessing risk of DGF in a patient, who has been diagnosed with EGF; and a kit comprising at least one component for assaying urine from a patient for NGAL and instructions for assaying the urine for NGAL and assessing cadaveric kidney transplant function or risk of DGF in the patient.09-22-2011
20110244500Gel electrophoresis method useful for resolution and characterization of nerve tissue ultra high molecular weight protein aggregates - The instant disclosure describes an electrophoretic procedure capable of resolving and isolating ultra high molecular weight (MW) protein aggregates from nerve tissue. The procedure is based on the use of composite agarose-polyacrylamide gel electrophoresis (CAPAGE) and resolves proteins and protein aggregates over the range of from approximately 225 kDa to approximately 30,000 kDa. Triton X-100 precipitation is used to obtain a cytoskeleton protein fraction that is subsequently resuspended and subjected to gel electrophoresis. This method demonstrates that a protein aggregate of approximately 30,000 kDa is characteristic of normal murine spinal cord tissue and that the amount of said protein aggregate is increased in spinal cord homogenate obtained from transgenic mice bearing copies of a mutant human gene characteristic of familial amyotrophic lateral sclerosis. This method for separating nerve tissue ultra high MW cytoskeleton protein aggregates can prove useful in a variety of future biophysical and pharmacological studies related to the etiologies of Charcot-Marie-Tooth disease, Alzheimer's disease, Parkinson's disease, diseases based on expansions in tandem DNA repeats, spinal muscular atrophy, Friedreich's ataxia, giant axon neuropathy, juvenile ceroid-lipofuscinosis, amyotrophic lateral sclerosis, diabetic polyneuropathy and Down's syndrome.10-06-2011
20110275104Device and Method for Detection of Humidity-Compromised Urine Test Strips - The timing of the reaction of moisture-sensitive reagents for detecting the presence of analytes, e.g. leukocytes in urine samples, is used to detect when the reagents have been compromised by excess humidity. The ratio of light reflectance at wavelengths characteristic of the products of reaction between the reagents and the analyte and an infra-red reference dye is measured at two preset times after a urine sample has been applied to a test strip and used to determine whether the reagents have been compromised by excessive humidity. The presence of unusually dark samples is determined from the reflected light at 470 and 625 nm in order to confirm that the test strips are humidity-compromised.11-10-2011
20100317044MASS SPECTROMETRIC ENDOPEPTIDASE ASSAY - The activity of a selected endopeptidase in a body fluid is determined by the mass spectrometric measurement of the reaction products of reporter substrate molecules added to the body fluid. Each reporter substrate molecule includes a peptide with the cleavage motif of the endopeptidase, an anchor group A1 on one side of the cleavage site and a different anchor group A2 on the other side of the cleavage site. One anchor is used to extract the reporter substrate molecules from the body fluid and the other anchor is used to extract digest fragments of the reporter molecules from the body fluid. Mass markers allow several reporter substrates to be used simultaneously in the same body fluid sample to measure the activity of different types of endopeptidase.12-16-2010
20130189719ENZYME DETECTION - An enzyme detection product (07-25-2013
20130157300METHODS OF QUANTIFYING EXOSOME IN CELL CULTURE AND METHOD OF INCREASING RECOVERY RATE OF EXOSOME USING THE SAME - A method of detecting and recovering of exosomes in a sample, as well as a method of determining the recovery rate of exosomal recovery, and a method of screening for a material that induces secretion of the exosomes in a sample, which methods employ the use of a protease.06-20-2013
20120282642METHODS FOR MEASURING THE METABOLISM OF NEURALLY DERIVED BIOMOLECULES IN VIVO - The present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for neurological and neurodegenerative diseases and disorders, such as Alzheimer's Disease, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. Methods of measuring the in vivo metabolism of biomolecules produced in the CNS in a subject are provided.11-08-2012
20120282641METHOD OF IDENTIFYING PEPTIDES - Methods of identifying polypeptides have been developed using a de novo sequencing technique. Methods use photodissociation and low-energy fragmentation and the spectra of peptide ions obtained therefrom, such as obtained by post-source decay (PSD), have been developed. The methods include photodissociation and the spectra therefrom obtainable from treating ions with predetermined wavelengths of radiation in the vacuum ultraviolet range of the electromagnetic spectrum. The confidence of amino acid assignments based on x-type ions is evaluated by observing complementary y-, v- and w-type ions that provide additional constraints to sequence identification.11-08-2012
20120282640METHODS OF MEASURING CELL VIABILITY IN TISSUE ENGINEERED PRODUCTS - This invention provides methods of measuring the viability of cultured cells by detecting one or more cell death-stable proteins or enzyme activities. Methods provided by the invention correlate viability to relative levels of enzyme activity in cell-containing and non-cell-containing fractions of a cell culture.11-08-2012
20130183704Labeling Agent and Methods for Simultaneous Sequencing and Quantification of Multiple Peptides and Proteins Using the Same - The present invention provides a compound that can utilize hydrogen isotope and, at the same time, can quantify multiplexed samples at one time, as well as decreasing the cost for synthesis of the labeling agent. In addition, the present invention provides a novel method for quantitatively analyzing protein and peptide analytes having different quantities form each other using the labeling agent, wherein y-type fragment ions having a high mass which comprises the analyte remained after coupling the labeling agent with the analyte and then removing a part of the labeling agent through tandem mass spectrometry are utilized to conduct the quantitative analysis.07-18-2013
20130183702PROTEASE SELECTIVE SUPRAMOLECULAR ASSEMBLIES - Supramolecular assemblies for delivering active agents to cancerous or precancerous tissues in a subject are provided. These supramolecular assemblies are also useful in assays for detecting and imaging of cancerous and precancerous cells. The assemblies are protease-sensitive and comprise a peptide linkage containing a protease consensus sequence. The assemblies can be selectively targeted to cancerous tissue where the protease enzymes degrade the peptide linkage thereby releasing the active agents which were physically or mechanically contained in or retained by the supramolecular assembly.07-18-2013
20110312010COMPARISON OF PROTEIN SAMPLES - Methods of qualitatively and/or quantitatively detecting the presence of mutations, modifications or impurities in a protein sample are provided. The methods utilize isotopically labeled variants of amino acids incorporated into proteins prior to protein digest to enable comparisons of two protein samples in bottom-up liquid chromatography.12-22-2011
20110312009COMPOSITION FOR ASSAYING GLYCATED PROTEINS - Compositions for accurately assaying a glycated protein by: 1) avoiding effects of globulin and ascorbic acid components, 2) stabilizing proteases and at least enzymes acting on glycated amino acids; 3) accurately assaying albumin; and 4) assaying glycated albumin while avoiding the effects of glycated hemoglobin, and an assay method are provided. Thus, the contents of a glycated protein and glycated albumin can be more accurately determined.12-22-2011
20120015389METHOD AND DEVICE FOR MEASURING THE ACTIVITY OF ENZYMES AFTER DE-INHIBITION - The present invention relates to a method for measuring the activity of enzymes in a sample which contains at least one enzyme and at least one enzyme inhibitor corresponding to said enzyme, whereby after de-inhibition the activity of the released enzyme is measured in such a way that a substrate is added to the sample and the time course of the concentration of at least one reaction product (cleavage product) is recorded and the enzyme specific substrate has a fluorogenic part which is cleaved in the enzymatic reaction and the fluorescence (measuring parameter) of which can be detected in a wavelength range where the measuring parameter can be assigned unambiguously to the enzyme activity to be measured, whereby the de-inhibition is carried out by immersing a rigid carrier, to which the inhibitor binding substance is bound, into the sample. The present invention relates also to a corresponding device for measuring the activity on enzymes in a sample.01-19-2012
20120021446Evaluation Peptide For Use In Quantification Of Protein Using Mass Spectrometer, Artificial Standard Protein, And Method For Quantifying Protein - Disclosed is an evaluation peptide for evaluating the efficiency of a pretreatment in the quantification of a protein using a mass spectrometer, having high reliability and high general versatility. Also disclosed is an artificial standard protein comprising the evaluation peptide. Further disclosed is a method for quantifying a protein utilizing the artificial standard protein. Specifically disclosed is a method for selecting a peptide which consists of an amino acid sequence not agreeing with that in a naturally occurring protein and a variant thereof and capable of being detected by mass spectrometry and which has an amino acid that can be recognized by a protein-digesting enzyme, and using the peptide as an evaluation peptide for use in the quantification of a protein by a mass spectrometer.01-26-2012
20120028286METHOD FOR EVALUATING THE BREAKDOWN OF PROTEINS, POLYPEPTIDES AND PEPTIDES - Provided is an assay for determining the protein, polypeptide, and peptides degradation of a sample. The assay for determining the protein, polypeptide, and peptides degradation of a sample includes contacting the sample with a non-fluorescent compound whereby the non-fluorescent compound reacts with free primary amine in the sample from degradation of protein, polypeptide, and peptides in the sample producing a fluorescent signal to thereby measure the increase in protein, polypeptide, and peptides fragments in the sample and comparing the fluorescent signal to a standard to thereby quantify the amount of protein, polypeptide, and peptides degradation. By taking the ratio of this increase to protein concentrations measured using standard protein assays a sensitive measure of protein degradation is obtained.02-02-2012
20120028285Clickable cross-linker - A clickable cross-linker compound provides an easily scanned reporter ion for effective and efficient cross-linking and identification of intermolecular and intramolecular interactions of proteins and peptides.02-02-2012
20130203098Enzyme Sensors, Methods for Preparing and Using Such Sensors, and Methods of Detecting Protease Activity - Embodiments of the present disclosure provide for enzyme sensors, protease sensors, methods for producing and using the enzyme and protease sensors, methods of detecting and/or measuring protease activity, methods for characterizing protease cellular activity, fusion proteins, polynucleotides, and vectors corresponding to the enzyme and protease sensors, kits, and the like.08-08-2013
20130210050PROTEASE FOR PROTEOMICS - Provided herein is technology relating to proteases and proteomics and particularly, but not exclusively, to compositions comprising OmpT, methods of using OmpT, and methods of manufacturing OmpT for proteomics.08-15-2013
20130210051ANALYTE MASS SPECTROMETRY QUANTITATION USING A UNIVERSAL REPORTER - Quantitation of analytes, including but not limited to peptides, polypeptides, and proteins, in mass spectrometry using a labeled peptide coupled to a reporter, and a universal reporter.08-15-2013

Patent applications in class Involving proteinase